Form 10-Q

0001513162-20-000216.txt : 20201015 0001513162-20-000216.hdr.sgml : 20201015 20201015161528 ACCESSION NUMBER: 0001513162-20-000216 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20200831 FILED AS OF DATE: 20201015 DATE AS OF CHANGE: 20201015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMERICA INC CENTRAL INDEX KEY: 0000073290 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 952645573 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37863 FILM NUMBER: 201241638 BUSINESS ADDRESS: STREET 1: 17571 VON KARMAN AVENUE CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9496452111 MAIL ADDRESS: STREET 1: 17571 VON KARMAN AVENUE CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: NMS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19871130 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19830216 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR INSTRUMENTS INC DATE OF NAME CHANGE: 19720508 10-Q 1 form10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2020

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-37863

BIOMERICA, INC.

--------------------------------------------------------------------------------------------

(Exact name of registrant as specified in its charter)

Delaware 95-2645573

--------------------------------------------------------------------------------------------

(State or other jurisdiction of (I.R.S. Employer

incorporation or organization) Identification No.)

17571 Von Karman Avenue, Irvine, CA 92614

--------------------------------------------------------------------------------------------

(Address of principal executive offices) (Zip Code)

Registrant's telephone number including area code: (949) 645-2111

--------------------------------------------------------------------------------------------

(Former name, former address and former fiscal year, if changed since last report.)

(TITLE OF EACH CLASS) (NAME OF EACH EXCHANGE ON WHICH REGISTERED)

--------------------- -------------------------------------------

Common, par value $.08 NASDAQ Capital Market

Securities registered pursuant to Section 12(g) of the Act:

(TITLE OF EACH CLASS)

COMMON STOCK, PAR VALUE $0.08

Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [_]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [_]

Indicate by check mark whether the registrant is a large accelerated, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [_] Accelerated Filer [_]

Non-Accelerated Filer [_] Smaller Reporting Company [X]

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes [_] No [X]

Indicate the number of shares outstanding of each of the registrant's common stock, as of the latest practicable date 11,752,589 shares of common stock, par value $0.08, as of October 15, 2020.

BIOMERICA, INC.

INDEX

PART I	Financial Information

Item 1.	Financial Statements:

	Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) – Three Months Ended August 31, 2020 and 2019	1

	Condensed Consolidated Balance Sheets (unaudited) August 31, 2020 and (audited) May 31, 2020	2-3

	Condensed Consolidated Statement of Shareholders’ Equity – (unaudited) Three Months Ended August 31, 2020	4

	Condensed Consolidated Statements of Cash Flows (unaudited) - Three Months Ended August 31, 2020 and 2019	5

	Notes to Condensed Consolidated Financial Statements (unaudited)	6-12

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12-15

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	15

Item 4.	Controls and Procedures	15

PART II	Other Information

Item 1.	Legal Proceedings	15-16

Item 1A.	Risk and Uncertainties	16-17

Item 2.	Unregistered Sales of Equity Securities & Use of Proceeds	18

Item 3.	Defaults upon Senior Securities	18

Item 4.	Mine Safety Disclosures	18

Item 5.	Other Information	18

Item 6.	Exhibits	18

	Signatures	19

Table of Contents

PART I - FINANCIAL INFORMATION

SUMMARIZED FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIOMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS (UNAUDITED)

	Three Months Ended
	August 31, 2020		August 31, 2019

Net sales	$	1,143,806	$	1,194,415
Cost of sales		(960,930)		(827,111)
Gross Profit		182,876		367,304

Operating Expenses:
Selling, general and administrative		1,164,564		506,397
Research and development		674,693		370,466
Total operating expense		1,839,257		876,863

Loss from operations		(1,656,381)		(509,559)

Other Income:
Dividend and interest income		8,091		4,063
Total other income		8,091		4,063

Loss before income taxes		(1,648,290)		(505,496)

Provision for income taxes		1,125		800

Net loss	$	(1,649,415)	$	(506,296)

Basic net loss per common share	$	(0.14)	$	(0.05)

Diluted net loss per common share	$	(0.14)	$	(0.05)

Weighted average number of common and common equivalent shares:
Basic		11,748,377		9,744,461

Diluted		11,748,377		9,744,461

Net loss	$	(1,649,415)	$	(506,296)

Other comprehensive loss, net of tax:
Foreign currency translation		(1,721)		(3,442)

Comprehensive loss	$	(1,651,136)	$	(509,738)

The accompanying notes are an integral part of these statements.

Table of Contents

BIOMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	August 31, 2020 (unaudited)		May 31, 2020 (audited)
	August 31, 2020 (unaudited)		May 31, 2020 (audited)

Assets

Current Assets:
Cash and cash equivalents	$	6,964,314	$	8,641,027
Accounts receivable, less allowance for doubtful accounts of $272,356 and $70,981 as of August 31, 2020 and May 31, 2020, respectively		1,583,420		1,765,871
Inventories, net		4,101,404		2,850,836
Prepaid expenses and other		470,934		1,509,083
Total current assets		13,120,072		14,766,817

Property and Equipment, net of accumulated depreciation and amortization of $1,894,375 and $1,867,643 as of August 31, 2020 and May 31, 2020, respectively		292,235		279,379

Right of Use Assets, net of accumulated amortization of $288,746 and $231,489 as of August 31, 2020 and May 31, 2020, respectively		1,654,253		1,711,510

Investments		165,324		165,324

Intangible Assets, net of accumulated amortization of $501,962 and $496,124 as of August 31, 2020 and May 31, 2020, respectively		215,975		168,655

Other Assets		444,631		168,193
Total Assets	$	15,892,490	$	17,259,878

The accompanying notes are an integral part of these statements.

Table of Contents

BIOMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS - Continued

	August 31, 2020 (unaudited)		May 31, 2020 (audited)
	August 31, 2020 (unaudited)		May 31, 2020 (audited)
Current Liabilities:
Accounts payable and accrued expenses	$	1,270,913	$	986,711
Accrued compensation		309,345		278,627
Lease liability, current portion		221,201		211,809
Total current liabilities		1,801,459		1,477,147
Lease Liability, net of current portion		1,510,406		1,569,678
Total Liabilities		3,311,865		3,046,825

Commitments and Contingencies (Notes 5 and 6)		-		-

Shareholders' Equity:

Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020		25,714		25,714
Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020		-		-
Common stock, $0.08 par value, 25,000,000 shares authorized, 11,752,589 and 11,740,089 issued and outstanding at August 31, 2020 and May 31, 2020, respectively		940,205		939,205
Additional paid-in-capital		35,231,415		35,213,707
Accumulated other comprehensive loss		(41,562)		(39,841)
Accumulated deficit		(23,575,147)		(21,925,732)
Total Shareholders' Equity		12,580,625		14,213,053
Total Liabilities and Shareholders' Equity	$	15,892,490	$	17,259,878

The accompanying notes are an integral part of these statements.

Table of Contents

BIOMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited)

Three Months Ended August 31, 2020

	Common Stock			Series A 5% Convertible Preferred Stock			Additional Paid-in Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit
	Shares	Amount		Shares	Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Total

Balances, May 31, 2020	11,740,089	$	939,205	321,429	$	25,714	$	35,213,707	$	(39,841)	$	(21,925,732)	$	14,213,053

Exercise of stock options	12,500		1,000	-		-		13,900		-		-		14,900
Foreign currency translation	-		-	-		-		-		(1,721)		-		(1,721)
Compensation expense in connection with options granted	-		-	-		-		3,808		-		-		3,808
Net loss	-		-	-		-		-		-		(1,649,415)		(1,649,415)

Balances, August 31, 2020	11,752,589	$	940,205	321,429	$	25,714	$	35,231,415	$	(41,562)	$	(23,575,147)	$	12,580,625

The accompanying notes are an integral part of these statements.

Table of Contents

BIOMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Three Months Ended
	August 31, 2020		August 31, 2019
Cash flows from operating activities:

Net loss	$	(1,649,415)	$	(506,296)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		32,570		35,278
Change in provision for allowance on accounts receivable		201,375		(6,967)
Inventory reserve		5,005		2,320
Stock option expense		3,808		5,850
Reduction in deferred rent liability		-		(37,971)
Amortization of right-of-use asset		57,257		102,456
Changes in assets and liabilities:
Accounts receivable		(18,924)		603,107
Inventories		(1,255,573)		(57,568)
Prepaid expenses and other assets		1,038,149		(41,165)
Reduction in lease liability		(49,880)		(54,796)
Other assets		(276,438)		-
Accounts payable and accrued expenses		284,202		(55,718)
Accrued compensation		30,718		3,316
Net cash used in operating activities		(1,597,146)		(8,154)

Cash flows from investing activities:
Increase in intangibles		(53,158)		(12,100)
Purchases of property and equipment		(39,588)		(2,171)
Net cash used in investing activities		(92,746)		(14,271)

Cash flows from financing activities:
Proceeds from sale of common stock, net		-		112,608
Proceeds from exercise of stock options		14,900		34,028
Net cash provided by financing activities		14,900		146,636

Effect of exchange rate changes in cash		(1,721)		(3,442)
Net (decrease) increase in cash and cash equivalents		(1,676,713)		120,769

Cash and cash equivalents at beginning of period		8,641,027		686,785

Cash and cash equivalents at end of period	$	6,964,314	$	807,554

Supplemental Disclosure of Cash-Flow Information:
Cash paid during the period for:
Interest		-	$	-
Income taxes	$	1,125		-
Non-cash investing and financing activities:
Establishment of Right-Of-Use Asset per ASC 842	$	-	$	1,942,999
Establishment of Lease Liability per ASC 842	$	-	$	1,980,970

The accompanying notes are an integral part of these statements.

Table of Contents

BIOMERICA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1: BASIS OF PRESENTATION

Biomerica, Inc. and Subsidiaries (collectively "the Company") are primarily engaged in the development, manufacture and marketing of medical diagnostic products.

The Company develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and other medical conditions. The Company’s medical diagnostic products are sold worldwide in two markets: 1) clinical laboratories and 2) point of care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations.

The information set forth in these condensed consolidated financial statements is unaudited and reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc. and subsidiaries, for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. All adjustments that were made are of a normal recurring nature.

The unaudited, Condensed Consolidated Financial Statements and notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in our annual financial statements and notes. The condensed consolidated balance sheet data as of May 31, 2020 was derived from audited financial statements. The accompanying interim condensed consolidated financial statements should be read in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on August 31, 2020 for the fiscal year ended May 31, 2020. The results of operations for our interim periods are not necessarily indicative of results to be achieved for our full fiscal year.

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.

ACCOUNTING ESTIMATES

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based information). Actual results could materially differ from those estimates.

CONCENTRATION OF CREDIT RISK

The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. As of August 31, 2020, the Company had approximately $6,758,700 of uninsured cash. The Company does not believe it is exposed to significant credit risks.

For the quarters ended August 31, 2020 and August 31, 2019, the Company had two distributors and one distributor which accounted for 40.1% and 45.8% of net consolidated sales, respectively. At August 31, 2020 and May 31, 2020 the Company had two distributors and three distributors which accounted for a total of 62.1% and 80.0%, respectively, of gross accounts receivable. Of the 62.1% as of August 31, 2020, 43.6% was owed by a distributor in South America.

Table of Contents

For the quarters ended August 31, 2020 and 2019, two vendors accounted for approximately 63.8% and two vendors which accounted for 47.5% of the purchases or raw materials, respectively. As of August 31, 2020 and May 31, 2020 the Company had 3 vendors and 2 vendors which accounted for 50.0% and 26.9%, respectively, of accounts payable.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.

ACCOUNTS RECEIVABLE

The Company extends unsecured credit to its customers located throughout the United States and the world. International accounts are normally required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. For receivables over ninety days old, the Company begins to reserve a portion of the balance unless collection is reasonably assured.

Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.

INVENTORIES

The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.

Inventories approximate the following at:

	August 31,2020		May 31,2020
	August 31,2020		May 31,2020

Raw materials	$	2,219,000	$	1,635,000
Work in progress		890,000		988,000
Finished products		992,000		228,000
Total	$	4,101,000	$	2,851,000

Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of August 31, 2020 and May 31, 2020, inventory reserves were approximately $72,000 and $67,000, respectively.

PROPERTY AND EQUIPMENT, NET

Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income.

Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $26,732 and $29,498 for the three months ended August 31, 2020 and 2019, respectively.

Table of Contents

INTANGIBLES ASSETS, NET

Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $5,838 and $5,780 for the three months ended August 31, 2020 and 2019, respectively.

The Company assesses the recoverability of these intangible assets by determining whether the amortization of the assets balances over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of August 31, 2020 or 2019.

INVESTMENTS

From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be greater than the fair value. The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.

SHARE-BASED COMPENSATION

The Company follows the guidance of the accounting provisions of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.

The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2020:

		Exercise Price Weighted Average

	Option Shares
	Option Shares
Outstanding May 31, 2020	1,789,251	$	2.75
Granted	171,000		7.46
Exercised	(12,500)		1.20
Cancelled or expired	(22,001)		3.43
Outstanding August 31, 2020	1,925,750	$	3.17

During the three months ended August 31, 2020, options to purchase 12,500 shares of common stock were exercised at price of $1.20. Total net proceeds to the Company were $14,900.

During the three months ended August 31, 2020, the Company granted 171,000 options to purchase common stock at an average purchase price of $7.46.

Table of Contents

REVENUE RECOGNITION

The Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of August 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physician’s office products are sold to physicians and distributors, all of whom are categorized below according to the type of product sold to them. The Company also manufactures certain components on a contract basis for domestic and international manufacturers.

Disaggregation of revenue:

The following is a breakdown of revenues according to markets to which the products are sold:

	Three Months Ended
	August 31,2020		August 31,2019

Clinical lab	$	581,708	$	890,152
OTC		184,908		199,209
Physician's office		197,331		45,222
Contract Manufacturing		179,859		59,832
Total	$	1,143,806	$	1,194,415

See Note 4 for additional information regarding revenue concentrations.

SHIPPING AND HANDLING FEES

The Company includes shipping and handling fees billed to customers in net sales.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred. The Company expensed $674,693 and $370,466 of research and development costs during the quarters ended August 31, 2020 and 2019, respectively.

INCOME TAXES

The Company has provided a valuation allowance on deferred income tax assets of approximately $3,522,000 and $3,175,000 as of August 31, 2020 and May 31, 2020, respectively.

FOREIGN CURRENCY TRANSLATION

The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the quarters ended August 31, 2020 and 2019.

RIGHT-OF-USE ASSETS AND LEASE LIABILITY

The Company follows the guidance of ASC 842, Leases, which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. The Company leases office space and copy machines, all of which are operating leases. The Company has elected to exclude short-term leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term.

Table of Contents

NET LOSS PER SHARE

Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per share calculation for the three months ended August 31, 2020 and 2019 was 1,925,750 and 1,416,584, respectively. The Company also has outstanding 321,429 of series A 5% convertible preferred stock, which may be converted at any time to common stock.

RECENT ACCOUNTING PRONOUNCEMENTS

Recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

NOTE 3: SHAREHOLDERS’ EQUITY

On July 20, 2020, the Company’s outstanding SEC Form S-3 “Shelf” registration statement dated July 20, 2017 expired. This prior registration statement registered an indeterminant number of shares equating to a maximum aggregate offering amount of $45,000,000 of shares.

NOTE 4: GEOGRAPHIC INFORMATION

Financial information about foreign and domestic operations and export sales is approximately as follows:

	Three Months Ended
	August 31, 2020		August 31, 2019
Revenues from sales to unaffiliated customers:
United States	$	134,000	$	115,000
Asia		347,000		663,000
Europe		591,000		301,000
South America		43,000		47,000
Middle East		29,000		68,000
	$	1,144,000	$	1,194,000

As of August 31, 2020 and May 31, 2020, approximately $587,000 and $613,000 of Biomerica’s gross inventory and approximately $30,000 and $31,000, of Biomerica’s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.

NOTE 5: LEASES

On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. In November 2015, the Company signed the First Amendment to extend the lease until August 31, 2021. As of September 1, 2020, the rent was $23,637 per month.

In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The rent is currently $3,239 per month. The Company has one 10-year option to renew at the end of the initial lease period. Biomerica, Inc. is not a guarantor of such lease. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office on a month-to-month basis in Lindau, Germany, as headquarters for BioEurope GmbH, its Germany subsidiary.

Table of Contents

Components of lease expense include fixed lease expense of $85,946 for the three months ended August 31, 2020. For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company’s office and equipment leases generally have contractually specified minimum rent and annual rent increases which are included in the measurement of the right-of-use asset and related lease liability. Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred.

Supplemental cash flow information related to leases for the three months ended August 31, 2020:

Operating cash flows from operating leases	$	78,561

Right-of-use assets obtained in exchange for new operating lease liabilities		--
Weighted average remaining lease term (in years)		6.02
Weighted average discount rate		6.5	%

The maturity of lease liabilities as of August 31, 2020 are as follows:

Fiscal Years ending May 31st:
2021	$	161,927
2022		236,391
2023		262,810
2024		291,328
2025		322,098
Thereafter		457,053
Total	$	1,731,607

NOTE 6: COMMITMENTS AND CONTINGENCIES

Contracts and Licensing Agreements

On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (“Telcon Agreement”) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (“Telcon”), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica’s new InFoods® IBS products (“IBS Products”) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the US FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final US FDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC.

The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica’s starting clinical trials in the United States, receipt of US FDA clearance and Telcon’s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid.

Additionally, the Telcon Agreement provides for a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon. In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon’s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019. In September 2017, the Telcon Agreement was amended to extend the date by which Telcon must attain Korean FDA approval until April 30, 2020. During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021.

Table of Contents

On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica InFoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850.

As disclosed in the Form 10K filed with the SEC on August 31, 2020, on July 2, 2020, the Company received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. The Company is continuing to cooperate fully with the SEC’s investigation and provide information as requested. At this time, the Company is unable to predict the duration, scope or outcome of this investigation.

NOTE 7: SUBSEQUENT EVENTS

On September 15, 2020, the Company entered into an agreement with Public Health England research institution for the purpose of evaluating the Company’s COVID-19 Rapid Test.

On October 5, 2020, the Company entered into a sales agreement with a Ukrainian distributor. The agreement covers a four-year period and the total contract is valued at $480,000.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EXCEPT FOR HISTORICAL INFORMATION CONTAINED HEREIN, THE STATEMENTS IN THIS QUARTERLY REPORT ON FORM 10-Q MAY BE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 27A OF THE SECURITIES ACT OF 1933. FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES WHICH MAY CAUSE BIOMERICA'S RESULTS IN FUTURE PERIODS TO DIFFER MATERIALLY FROM FORECASTED RESULTS.

Like other businesses, THE COMPANY IS susceptible to macroeconomic downturns in the United States or abroad, as were experienced recently, that may affect the general economic climate and OUR performance or OUR customers. Aside from general macroeconomic downturns, the additional material factors, RISKS AND UNCERTAINTIES that could affect future financial results include, but are not limited to: THE CONTINUED DEMAND FOR THE COMPANY'S PRODUCTS; AVAILABILITY OF RAW MATERIALS; RESULTS OF RESEARCH AND DEVELOPMENT ACTIVITIES; THE ABILITY TO RETAIN KEY EMPLOYEES AND CUSTOMERS; THE ABILITY TO COLLECT RECEIVABLES FROM CUSTOMERS; THE CONTINUED ABILITY OF THE COMPANY TO ATTAIN AND MAINTAIN THE LICENSES AND APPROVALS REQUIRED;Regional or global pandemics and the economic and social disruptions these cause; terrorist attacks and the impact of such events; existing and potential increase in trade tariffs, especially with China; diminished or no access to raw materials that directly enter into our manufacturing process; shipping labor disruption or other major degradation of the ability to ship out products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the U.S. border due to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse effect on our revenues and profitability; possible costs in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of new adverse regulations or regulatory requirements; numerous competitors, some of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or medical professionals alleging harm caused by the use of or exposure to our products; recalls of products; inability to obtain FDA clearance on products or excessive costs incurred in order to obtain such approvals; regulatory actions taken by government agencies such as the FDA, SEC, USDA and other regulators; quarterly variations in operating results caused by a number of factors, including business and industry conditions; and other factors beyond our control. All these factors make it difficult to predict operating results for any particular period.

EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW, WE MAY NOT UPDATE OR REVISE OUR FORWARD-LOOKING STATEMENTS AND THE LACK OF SUCH UPDATE DOES NOT IMPLY THAT ACTUAL EVENTS ARE AS ORIGINALLY EXPRESSED BY SUCH FORWARD-LOOKING STATEMENTS. YOU SHOULD READ THE DISCLOSURES IN THIS REPORT AND OTHER REPORTS, WHICH WE FILE WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE RISK FACTORS CONTAINED THEREIN.

OVERVIEW

Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH), (the “Company”) is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians' offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs.

Table of Contents

Our primary focus is the research and development of revolutionary, patented diagnostic-guided therapy (“DGT”) products to treat gastrointestinal diseases, such as irritable bowel syndrome (“IBS”), and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. FDA, management believes the revenue potential to the Company is very significant.

Due to the global 2019 SARS-CoV-2 novel coronavirus (“COVID-19”) pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. These diagnostic tests use a patient’s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body’s immune response to a COVID-19 infection, even if the infection was asymptomatic. During the fourth quarter of fiscal 2020 we began marketing and selling outside of the U.S. a disposable rapid finger-prick blood test, which detects COVID-19 IgG/IgM antibodies within 10 minutes. This test is designed to be performed by trained professionals anywhere (e.g. airports, schools, work, pharmacies and doctors’ offices).

Following fiscal 2020 year-end we submitted to the FDA an application under an Emergency Use Authorization (“EUA”) to sell in the U.S.a lab-scale, high throughput ELISA COVID-19 antibody test kit that would be sold to labs and hospitals to perform COVID-19 antibody testing. The Company also anticipates selling this test kit outside of the U.S. under a CE Mark (European Conformity). Initial sales for this product are expected during the Company’s second quarter of fiscal 2021 assuming we receive EUA clearance. The Company manufactures this COVID-19 ELISA test on its automated equipment at the Company’s California facility that is also used to produce serology antibody tests for other diseases. Since we did not receive FDA clearance for this product during our first quarter of 2021, we did not record any sales in the U.S. for our COVID-19 ELISA products. Further, sales of our disposable rapid finger prick blood test, which is only authorized for sale outside of the U.S., were slower in the first quarter as we are told by customers that most government health agencies are focused on viral testing (determining who is currently infected) while the infection rates in the territories we serve showed lower overall cases. However, we believe that as vaccines become available in the market, demand for serology (antibody) tests, like those we produce, will greatly increase. In addition, the infection rates in the territories we serve have increased, which we believe will result in a higher demand for both antibody and viral testing. Vaccines are designed to create antibodies in individuals that will enable them to avoid serious illness when exposed to the COVID-19 virus. Therefore, following vaccination, patients will want to know if the vaccination worked and they have produced adequate levels of antibodies to the COVID-19 virus. Further, at various points following vaccination (i.e. 3 months, 6 months, 9 months, etc.), we anticipate people will want to receive an antibody test to determine if the level of, antibodies produced from the vaccine are still adequate to fight off a serious infection. Therefore, we believe demand for COVID-19 antibody testing will remain strong into the foreseeable future, even after demand for actual virus testing begins to fall.

Aside from the current focus on COVID-19 products in research, development and clinical trials, the products we continue to sell are primarily focused on gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Our products are CE marked and/or sold for diagnostic use where they are registered by each country’s regulatory agency. In addition, some products are cleared for sale in the U.S. by the FDA.

Finally, the Company continues to see progress in completing the testing required to attain FDA clearance for our patented InFoods® IBS DGT product that is designed to diagnose and treat sufferers of IBS. Recently we added most of the Mayo Clinic sites to our clinical trials for this product. Mayo Clinic joins Beth Israel Deaconess Medical Center Inc., a Harvard Medical School teaching hospital, University of Texas Health Science Center at Houston, Houston Methodist and the University of Michigan as other sites conducting the trials.

InFoods® IBS is a unique, patented product that can allow physicians to identify specific foods (e.g. pork, milk, onions, sugar, chickpeas, etc.) for each IBS patient, that when removed from that patient’s diet, may alleviate or improve their IBS symptoms and suffering.

Upon demonstrating efficacy and obtaining FDA approval, we believe the long-term opportunities for the InFoods IBS product could be comparable to any of the major drugs currently used to treat IBS.

Further, the United States Patent and Trademark Office (“USPTO”) has issued the Company two patents with broad claims that protect the InFoods® IBS product. Patents have also been issued in the countries of Japan, Korea and recently Singapore with many other patents still pending globally. Additional patents have also been filed for other diseases that utilize the InFoods® DGT technology platform which include: functional dyspepsia, Crohn’s Disease, ulcerative colitis, gastroesophageal reflux disease (“GERD”), migraine headaches, and osteoarthritis.

Table of Contents

RESULTS OF OPERATIONS

Consolidated net sales for Biomerica were $1,143,806 for the three months ended August 31, 2020 as compared to $1,194,415 for the same period in the previous year. This represents a decrease of $50,609, or 4.2%. The decrease was primarily due to decreased demand of approximately $355,000 in Asia and the Middle East which was due to lower sales to certain distributors and timing of certain orders. This was partially offset by an increase in sales of approximately $290,000 in Europe of contract manufacturing and COVID-19 tests. Sales in the U.S. were up by approximately $19,000 primarily due to increased sales to our drug store customers in the current quarter. The Company believes revenues during the quarter for sales of non-COVID-19 products were negatively impacted by the world-wide pandemic.

Consolidated cost of sales for the three months ended August 31, 2020 as compared to August 31, 2019 increased from $827,111 to $960,930, or by $133,819. The percentage of cost of sales relative to sales increased from 69.2% to 84.0%. The Company’s standard margin on products sold was similar to previous periods. However, during the three months ended August 31, 2020 the manufacturing facilities weren’t running at 100% capacity due to the negative impact COVID-19 had on sales of the Company’s non-COVID-19 products. This generated unfavorable manufacturing variances within our reported cost of sales.

Consolidated selling, general and administrative expense for the three months ended August 31, 2020 as compared to August 31, 2019 increased from $506,397 to $1,164,564, or by $658,167, or 130%. The increase was primarily due to legal expenses related to responding to the SEC inquiry discussed in Part II, as well as an increase in the allowance for doubtful accounts, additional consulting fees, and partly to increased personnel costs as the Company is expanding and strengthening its management team in sales, marketing, and administration.

Consolidated research and development expense for the three months ended August 31, 2020 as compared to August 31, 2019 increased from $370,466 to $674,693, or by $304,227, or 82.1%, primarily as a result of increases in costs related to the research, development and validation of COVID-19 tests, and increased costs related to initiation costs at Mayo Clinic, University of Houston Texas, and Methodist Hospital for clinical trials for our InFoods® IBS product.

Interest and dividend income for the three months ended August 31, 2020 as compared to August 31, 2019 increased from $4,063 to $8,091 for the same period.

LIQUIDITY AND CAPITAL RESOURCES

As of August 31, 2020 and May 31, 2020, the Company had cash and cash equivalents in the amount of $6,964,314 and $8,641,027 and working capital of $11,318,613 and $13,289,670, respectively. During the three months ended August 31, 2020, the Company’s operations used cash of $1,597,146 compared to cash used in operations of $8,154 in the same period of the prior fiscal year. Cash used by operations increased year to date in fiscal 2021 compared to year to date fiscal 2020 primarily due to cash related operating losses of $1,349,400, growth in inventory of $1,250,568 driven partly by an increase in COVID-19 inventory of $1,189,427, partially offset by a reduction in prepaids of $1,038,149 which was primarily driven by a repayment of an advance the Company had with one of our suppliers. Cash used in investing activities year to date in fiscal 2021 was $39,588 for purchases of fixed assets and $53,158 for increased intangibles compared to year to date in fiscal 2020 of $2,171, which was the result of property and equipment purchases and $12,100, for increases of intangibles. Cash provided by financing activities in fiscal year 2021 to date was $14,900 which was a result of stock option exercises, as compared to $34,028 in stock option exercises and $112,608 from the net proceeds from the sale of common stock in fiscal 2020.

We have been working on new products for the gastroenterology market. Patent applications for the new products have been filed and five patents have been issued (two in the USA and one each in Japan, Korea and Singapore). The Company has been working on obtaining additional patents and U.S. regulatory approvals. The Company has been spending significant funds on the research, development, patent and related costs and expects this will continue in order to obtain the desired patents and approvals.

On July 21, 2020, the Company filed with the SEC a new Form S-3 “Shelf” registration statement to replace the registration statement that expired on July 20, 2020. The new registration statement registers common shares to be issued in a maximum aggregate amount of $90,000,000. Included in this registration statement was the registration of all of the common shares issued, or to be issued, to Palm Global Small Cap Master Fund LP upon conversion of their convertible Preferred stock into common shares. This S-3 registration statement became effective September 30, 2020. The Company intends to use the net proceeds from this offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.

Table of Contents

OFF BALANCE SHEET ARRANGEMENTS

There were no off-balance sheet arrangements as of August 31, 2020.

CRITICAL ACCOUNTING POLICIES

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These relate to revenue recognition, bad debts, inventory overhead application, inventory reserve, lease liabilities and right-of-use assets. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial conditions or results of operations. We suggest that our significant accounting policies be read in conjunction with this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Please refer to Note 2 for information on Significant Accounting Policies.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Our management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives and the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at the "reasonable assurance" level. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective to ensure that information required to be disclosed in the reports that we file and submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms; and (2) accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during our last fiscal quarter that has materially affected, or that is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. There were no legal proceedings pending as of August 31, 2020.

Table of Contents

ITEM 1A. RISKS AND UNCERTAINTIES.

You should read the following factors in conjunction with the factors discussed elsewhere in this and our other filings with the Securities and Exchange Commission and in materials incorporated by reference in these filings such as the Form S-3 and Prospectus Supplement filed on July 21, 2020. The following is intended to highlight certain factors that may affect the financial condition and results of operations of Biomerica, Inc. and are not meant to be an exhaustive discussion of risks that apply to companies such as Biomerica, Inc. Like other businesses, Biomerica, Inc. is susceptible to macroeconomic downturns in the United States or abroad, as were experienced in recent history that may affect the general economic climate and performance of Biomerica, Inc. or its customers. Our results may fluctuate adversely as a result of many factors that are outside our control, which may negatively impact our stock price. Sales of our common stock in the public market could lower the market price for our common stock and the price of our stock could fluctuate unpredictably in response to various factors. The Company does not anticipate paying dividends in the foreseeable future, which could affect the market price of the stock.

Our business could be adversely affected by the effects of widespread public health epidemics.

We are susceptible to a widespread outbreak of an illness or other health issue, such as the recent COVID-19 Coronavirus outbreak first reported in Wuhan, Hubei Province, China in December 2019 and subsequently spreading throughout the world resulting in hundreds of thousands of confirmed cases worldwide and many deaths. The outbreak of the COVID-19 virus has caused the various governments, including the U.S., to implement quarantines, various restrictions on travel causing airlines to suspend international and certain domestic flights, shelter in place orders and other restrictions. Governments have also implemented work restrictions that prohibit many employees from going to work, and for businesses that are allowed to remain open, many employees are electing to remain at home to avoid spread of the disease. As a result of this COVID-19 virus outbreak and potential future pandemic outbreaks, the Company faces significant risks including, but not limited to: a) supply chain disruptions making it difficult for the Company to contract and receive materials needed for production of its products, and needed to ship finished products to our end customers, b) loss of contracts and customers from the financial strains or other disruptions they are experiencing as a result of the pandemic, c) financial risks pertaining to receivables due from customers that may fall into insolvency or otherwise be unable to pay their bills, d) government responses including orders that make it difficult to remain open for business, restrict imports of raw materials or exports of finished goods, refusal to allow the Company’s product to be licensed for sale in their countries, and other seen and unforeseen actions taken by government agencies, e) absenteeism or loss of employees at the Company, or at our partner’s companies, due to health reasons or government restrictions, that are needed to develop, validate, manufacture and perform other necessary functions for our operations, f) equipment failures, loss of utilities and other disruptions that could impact our operations or render them inoperable, g) litigation or government actions against the Company pertaining to existing products, new products sold by the Company that are directed at limiting or treating the spread of the pandemic outbreak, h) a local or global recession or depression that could harm the international banking system, limit demand for all products including those made by the Company, i) a drop in demand for our products, that are all medical related, due to patients’ reluctance or refusal to visit hospitals, labs, and doctors’ offices where our products are used due to their fear of contracting a disease, and many other seen and unforeseen events and circumstances, all of which could negatively impact the Company.

If our COVID-19 tests are unable to gain acceptance in the market, prove to be ineffective or less effective than expected, and/or we do not receive regulatory approvals for our COVID-19 tests to be sold, our results of operation could be materially harmed.

Table of Contents

Although we believe that our COVID-19 tests represent promising tests to detect prior COVID-19 virus exposure, the tests may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to establish a market for our COVID-19 antibody tests. Gaining acceptance in medical communities requires increasing awareness of our COVID-19 tests and their benefits. Also, there are a large number of companies around the world now making and selling COVID-19 tests that compete with our COVID-19 tests. Many of these competitor products are made in China and other parts of Asia where manufacturing costs are low. As such, we are seeing supply and price competition which could make it difficult for the Company to compete. Other risks pertaining to these products include:

•	our ability to demonstrate the efficacy, speed and cost competitiveness of our COVID-19 tests;

•	whether healthcare providers and governmental agencies believe our COVID-19 tests are sufficiently safe, effective, and accurate;

•	our ability to transfer, further develop, integrate and use third-party licensed technology;

•	our ability to manufacture and scale commercial products;

•	our ability to source required raw materials in a cost effective and timely manner;

•	mutations in the COVID-19 virus that render our tests ineffective;

•	receipt of regulatory approvals necessary prior to commercialization of our products;

•	the FDA or other regulatory agencies retracting their prior approval for our products to be sold in their market or changing regulations for approval; and

•	whether the medical community accepts our COVID-19 tests as a supplement to, alternative to, or complimentary to, current PCR or other tests for COVID-19 infection.

In addition, each country in which we wish to sell these tests has its own regulatory approval requirements. We will need to comply with the regulatory requirements of each country before we are permitted to sell in that country. There can be no assurance that governmental agencies, including the FDA, will provide clearance of our COVID-19 tests to be sold in their markets. Failure to achieve widespread market acceptance of our COVID-19 tests, or failure to achieve regulatory clearance of our COVID-19 tests, could materially harm our business, financial condition, and results of operations. Our COVID-19 tests are new tests that only generated revenue during the last two months of our prior fiscal year and for the current fiscal year. It is uncertain how long we will be able to generate revenues from these tests, and what level of sales, if any, we will attain in the future.

There is no assurance that we will be able to remain competitive and develop new products and markets for these products. Raising funds to support this development may be difficult and the inability to do so may impact our ability to develop these new products. Acceptance of these new products by health care providers and physicians could have a negative impact on future sales.

Our business is subject to regulation by various governmental agencies. Our results of operations could be negatively impacted by failures or delays in approvals or the loss of previously received approvals or changes to existing laws and regulations. Possible costs or difficulty in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of new adverse regulations or regulatory requirements could affect results adversely.

Interruptions in the supply of raw materials could adversely affect our operations and results. Inability to successfully control our margins is affected by many factors including competition and product mix.

The loss of key personnel and the inability to hire key personnel could affect the business. Aside from general macroeconomic downturns, the additional material factors that could affect future financial results include, but are not limited to: Terrorist attacks and the impact of such events; shipping labor disruption or other major degradation of the ability to ship out products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the U.S. border due to an escalation of terrorist or counter terrorist activity; additional governmental tariffs or other fees imposed by the U.S. government for the export of goods to China or other countries; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse effect on our revenues and profitability; numerous competitors, some of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or medical professionals alleging harm caused by the use of or exposure to our products; quarterly variations in operating results caused by a number of factors, including business and industry conditions; concentrations of sales with certain distributors-the loss of certain of these distributors could lead to significantly reduced sales, which have been increasing. This could adversely affect the results of the Company if the Company were to lose the sales of that distributor and other factors beyond our control; high balances carried on accounts receivables from concentrated customers could result in write-offs of accounts receivable; and the costs of recalls, should such occasion arise. All these factors make it difficult to predict operating results for any particular period.

Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS - None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES - None.

ITEM 4. MINE SAFETY DISCLOSURES - None.

ITEM 5. OTHER INFORMATION - None.

ITEM 6. EXHIBITS.

The following exhibits are filed or furnished as part of this quarterly report on Form 10-Q:


Exhibit No.				Description

	31.1		*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Zackary S. Irani

	31.2		*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Steve Sloan

	32.1		*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act — Zackary S. Irani

	32.2		*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act — Steve Sloan

		101 Interactive data files pursuant to Rule 405 Regulation S-T, as follows:
101.INS-XBRL Instance Document
101.SCH-XBRL Taxonomy Extension Schema Document 101.CAL-XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF–XBRL Taxonomy Extension Definition Linkbase Document 101.LAB-XBRL Taxonomy Extension Label Linkbase Document 101.PRE-XBRL Taxonomy Extension Presentation Linkbase Document

*Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has fully caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOMERICA, INC.

Date: October 15, 2020
	By:	/S/ Zackary S. Irani
		Zackary S. Irani
		Chief Executive Officer
		(Principal Executive Officer)

Date: October 15, 2020
	By:	/S/ Steve Sloan
		Steve Sloan
		Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 exhibit31_1.htm EXHIBIT 31.1 Exhibit 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Zackary S. Irani, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Biomerica, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of our internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or other persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 15, 2020

/s/ Zackary S. Irani

Zackary S. Irani

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 exhibit31_2.htm EXHIBIT 31.2 Exhibit 31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steve Sloan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Biomerica, Inc.;

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 15, 2020

/s/ Steve Sloan

Steve Sloan

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 exhibit32_1.htm EXHIBIT 32.1 Exhibit 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Biomerica, Inc. (the "Company") on Form 10-Q for the period ending August 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Zackary Irani, Chief Executive Officer of the Company, certify, to the best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002,

The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and

ii.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Zackary S. Irani

Zackary S. Irani

Chief Executive Officer

Date: October 15, 2020

EX-32.2 5 exhibit32_2.htm EXHIBIT 32.2 Exhibit 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Biomerica, Inc. (the "Company") on Form 10-Q for the period ending August 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steve Sloan, Chief Financial Officer of the Company, certify, to the best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002,

The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and

ii.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Steve Sloan

Steve Sloan

Chief Financial Officer

Date: October 15, 2020

EX-101.INS 6 bmra-20200831.xml XBRL INSTANCE DOCUMENT 0000073290 2020-06-01 2020-08-31 0000073290 2020-10-15 0000073290 2019-06-01 2019-08-31 0000073290 2020-08-31 0000073290 2020-05-31 0000073290 bmra:A5PercentConvertiblePreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-08-31 0000073290 bmra:A5PercentConvertiblePreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-05-31 0000073290 us-gaap:PreferredStockMember 2020-08-31 0000073290 us-gaap:PreferredStockMember 2020-05-31 0000073290 us-gaap:CommonStockMember 2020-05-31 0000073290 us-gaap:SeriesAPreferredStockMember bmra:A5PercentConvertiblePreferredStockMember 2020-05-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2020-05-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-05-31 0000073290 us-gaap:RetainedEarningsMember 2020-05-31 0000073290 us-gaap:CommonStockMember 2020-06-01 2020-08-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2020-06-01 2020-08-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-01 2020-08-31 0000073290 us-gaap:RetainedEarningsMember 2020-06-01 2020-08-31 0000073290 us-gaap:CommonStockMember 2020-08-31 0000073290 us-gaap:SeriesAPreferredStockMember bmra:A5PercentConvertiblePreferredStockMember 2020-08-31 0000073290 us-gaap:AdditionalPaidInCapitalMember 2020-08-31 0000073290 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-31 0000073290 us-gaap:RetainedEarningsMember 2020-08-31 0000073290 2019-05-31 0000073290 2019-08-31 0000073290 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-06-01 2020-08-31 0000073290 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-06-01 2019-08-31 0000073290 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-06-01 2020-08-31 0000073290 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-05-31 2020-05-31 0000073290 srt:SouthAmericaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-06-01 2020-08-31 0000073290 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2020-06-01 2020-08-31 0000073290 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2019-06-01 2019-08-31 0000073290 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2020-06-01 2020-08-31 0000073290 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2020-05-31 2020-05-31 0000073290 srt:MinimumMember 2020-06-01 2020-08-31 0000073290 srt:MaximumMember 2020-06-01 2020-08-31 0000073290 us-gaap:DistributionRightsMember 2020-06-01 2020-08-31 0000073290 bmra:PurchasedTechnologyRightsMember 2020-06-01 2020-08-31 0000073290 us-gaap:PatentsMember 2020-06-01 2020-08-31 0000073290 us-gaap:EmployeeStockOptionMember 2020-06-01 2020-08-31 0000073290 us-gaap:EmployeeStockOptionMember 2020-08-31 0000073290 us-gaap:EmployeeStockOptionMember 2020-05-31 0000073290 bmra:ClinicalLabMember 2020-06-01 2020-08-31 0000073290 bmra:ClinicalLabMember 2019-06-01 2019-08-31 0000073290 bmra:OTCMember 2020-06-01 2020-08-31 0000073290 bmra:OTCMember 2019-06-01 2019-08-31 0000073290 bmra:PhysiciansOfficeMember 2020-06-01 2020-08-31 0000073290 bmra:PhysiciansOfficeMember 2019-06-01 2019-08-31 0000073290 bmra:ContractManufacturingMember 2020-06-01 2020-08-31 0000073290 bmra:ContractManufacturingMember 2019-06-01 2019-08-31 0000073290 srt:MaximumMember us-gaap:CommonStockMember 2020-07-20 2020-07-20 0000073290 srt:MaximumMember us-gaap:CommonStockMember 2020-07-21 2020-07-21 0000073290 pf0:MX 2020-08-31 0000073290 pf0:MX 2020-05-31 0000073290 pf0:US 2020-06-01 2020-08-31 0000073290 pf0:US 2019-06-01 2019-08-31 0000073290 srt:AsiaMember 2020-06-01 2020-08-31 0000073290 srt:AsiaMember 2019-06-01 2019-08-31 0000073290 srt:EuropeMember 2020-06-01 2020-08-31 0000073290 srt:EuropeMember 2019-06-01 2019-08-31 0000073290 srt:SouthAmericaMember 2020-06-01 2020-08-31 0000073290 srt:SouthAmericaMember 2019-06-01 2019-08-31 0000073290 us-gaap:MiddleEastMember 2020-06-01 2020-08-31 0000073290 us-gaap:MiddleEastMember 2019-06-01 2019-08-31 0000073290 bmra:BuildingInIrvineCaliforniaMember 2009-06-18 2009-06-18 0000073290 pf0:MX us-gaap:PropertyAvailableForOperatingLeaseMember 2016-11-01 2016-11-30 0000073290 bmra:FirstAmendmentToLeaseMember bmra:BuildingInIrvineCaliforniaMember 2009-06-18 2009-06-18 0000073290 bmra:TelconAgreementMember 2016-05-25 0000073290 bmra:TelconAgreementMember 2016-05-25 2016-05-25 0000073290 bmra:UniversityOfTexasHealthScienceCenterMember 2020-06-25 0000073290 bmra:UkrainianDistributorMember us-gaap:SubsequentEventMember 2020-10-05 2020-10-05 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 2020-08-31 BIOMERICA INC Yes Yes Non-accelerated Filer true false false --05-31 Q1 2021 10-Q 0000073290 false 11752589

1143806

1194415

960930

827111

182876

367304

1164564

506397

674693

370466

1839257

876863

-1656381

-509559

8091

4063

8091

4063

-1648290

-505496

1125

800

-1649415

-506296

-0.14

-0.05

-0.14

-0.05

11748377

9744461

11748377

9744461

-1721

-3442

-1651136

-509738

6964314

8641027

1583420

1765871

4101404

2850836

470934

1509083

13120072

14766817

292235

279379

1654253

1711510

165324

215975

168655

444631

168193

15892490

17259878

1270913

986711

309345

278627

221201

211809

1801459

1477147

1510406

1569678

3311865

3046825

25714

940205

939205

35231415

35213707

-41562

-39841

-23575147

-21925732

12580625

14213053

15892490

17259878

272356

70981

1894375

1867643

288746 231489

501962

496124

0.08

571429

321429

4428571 4428571

0.08

25000000

11752589

11740089

11752589

11740089

939205

321429

25714

35213707

-39841

-21925732

12500

1000

13900

14900

-1721

3808

-1649415

11752589

940205

321429

25714

35231415

-41562

-23575147

32570

35278

201375

-6967

5005

2320

3808

5850

-37971 57257 102456

18924

-603107

1255573

57568

-1038149

41165

-49880 -54796

276438

284202

-55718

30718

3316

-1597146

-8154

53158

12100

39588

2171

-92746

-14271

112608

14900

34028

14900

146636

-1721

-3442

-1676713

120769

686785

807554

1125

1942999 1980970

<div style="font-family: "Courier New"; font-size: 10pt; "> NOTE 1:  BASIS OF PRESENTATION Biomerica, Inc. and Subsidiaries (collectively "the Company") are primarily engaged in the development, manufacture and marketing of medical diagnostic products.  The Company develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and other medical conditions. The Company’s medical diagnostic products are sold worldwide in two markets: 1) clinical laboratories and 2) point of care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. The information set forth in these condensed consolidated financial statements is unaudited and reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc. and subsidiaries, for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. All adjustments that were made are of a normal recurring nature. The unaudited, Condensed Consolidated Financial Statements and notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in our annual financial statements and notes. The condensed consolidated balance sheet data as of May 31, 2020 was derived from audited financial statements. The accompanying interim condensed consolidated financial statements should be read in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on August 31, 2020 for the fiscal year ended May 31, 2020. The results of operations for our interim periods are not necessarily indicative of results to be achieved for our full fiscal year. </div>

<div style="font-family: "Courier New"; font-size: 10pt; "> NOTE 2:  SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. ACCOUNTING ESTIMATES The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based information). Actual results could materially differ from those estimates. CONCENTRATION OF CREDIT RISK The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.  As of August 31, 2020, the Company had approximately $6,758,700 of uninsured cash.  The Company does not believe it is exposed to significant credit risks. For the quarters ended August 31, 2020 and August 31, 2019, the Company had two distributors and one distributor which accounted for 40.1% and 45.8% of net consolidated sales, respectively.  At August 31, 2020 and May 31, 2020 the Company had two distributors and three distributors which accounted for a total of 62.1% and 80.0%, respectively, of gross accounts receivable.  Of the 62.1% as of August 31, 2020, 43.6% was owed by a distributor in South America.  For the quarters ended August 31, 2020 and 2019, two vendors accounted for approximately 63.8% and two vendors which accounted for 47.5% of the purchases or raw materials, respectively. As of August 31, 2020 and May 31, 2020 the Company had 3 vendors and 2 vendors which accounted for 50.0% and 26.9%, respectively, of accounts payable. CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. ACCOUNTS RECEIVABLE The Company extends unsecured credit to its customers located throughout the United States and the world. International accounts are normally required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.  Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper level management.  Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. For receivables over ninety days old, the Company begins to reserve a portion of the balance unless collection is reasonably assured.   Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables.   Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders. INVENTORIES The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. Inventories approximate the following at: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> <a name="OLE_LINK7"></a> </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" rowspan="2" valign="bottom">  August 31,2020</td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:13%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 13%; white-space: nowrap;" rowspan="2" valign="bottom"> May 31,2020</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Raw materials     </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2,219,000</td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:11%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 1,635,000</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:71%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 71%; white-space: nowrap;" valign="bottom"> Work in progress</td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 890,000</td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 988,000</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Finished products</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 992,000</td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 228,000</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 4,101,000</td> <td style="HEIGHT:15.75pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 2,851,000</td></tr></table> Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of August 31, 2020 and May 31, 2020, inventory reserves were approximately $72,000 and $67,000, respectively. PROPERTY AND EQUIPMENT, NET Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $26,732 and $29,498 for the three months ended August 31, 2020 and 2019, respectively. INTANGIBLES ASSETS, NET Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets <a name="OLE_LINK9"></a><a name="OLE_LINK8">that have indefinite </a>useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. <a name="OLE_LINK6">Amortization amounted to $5,838 and $5,780 for the three months ended August 31, 2020 and 2019, respectively. </a> The Company assesses the recoverability of these intangible assets by determining whether the amortization of the assets balances over its remaining life can be recovered through projected undiscounted future cash flows.  The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of August 31, 2020 or 2019. INVESTMENTS From time-to-time, the Company makes investments in privately-held companies.  The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable.  If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices.  The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be greater than the fair value.  The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment.  Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received. SHARE-BASED COMPENSATION The Company follows the guidance of the accounting provisions of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2020: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" rowspan="3" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" rowspan="4" valign="bottom"> Exercise Price Weighted Average</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%;" rowspan="2" valign="bottom"> Option Shares</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Outstanding May 31, 2020</td> <td style="HEIGHT:15.75pt; WIDTH:14%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 1,789,251</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2.75</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Granted</td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 171,000</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 7.46</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Exercised</td> <td style="HEIGHT:15pt; WIDTH:14%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> (12,500)</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.20</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Cancelled or expired</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> (22,001)</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3.43</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Outstanding August 31, 2020</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 1,925,750</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3.17</td></tr></table> During the three months ended August 31, 2020, options to purchase 12,500 shares of common stock were exercised at price of $1.20.  Total net proceeds to the Company were $14,900. During the three months ended August 31, 2020, the Company granted 171,000 options to purchase common stock at an average purchase price of $7.46. REVENUE RECOGNITION The Company has various contracts with customers.  All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes.  The Company evaluated the status of these contracts as of August 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods.  Services for some contract work are invoiced and recognized for work that has been performed as the project progresses.  The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physician’s office products are sold to physicians and distributors, all of whom are categorized below according to the type of product sold to them.  The Company also manufactures certain components on a contract basis for domestic and international manufacturers. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom">  </td> <td colspan="5" style="HEIGHT:15pt; WIDTH:34%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 34%; white-space: nowrap;" valign="bottom"> Three Months Ended</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> August 31,2020</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16.24%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> August 31,2019</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4.24%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Clinical lab</td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 581,708</td> <td style="HEIGHT:15pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:4.24%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 890,152</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> OTC</td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 184,908</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:4.24%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 199,209</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Physician's office</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 197,331</td> <td style="HEIGHT:15pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:4.24%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 45,222</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Contract Manufacturing</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 179,859</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4.24%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 59,832</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:66%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:3%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,143,806</td> <td style="HEIGHT:15.75pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:4.24%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,194,415</td></tr></table> See Note 4 for additional information regarding revenue concentrations. SHIPPING AND HANDLING FEES The Company includes shipping and handling fees billed to customers in net sales. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred.  The Company expensed $674,693 and $370,466 of research and development costs during the quarters ended August 31, 2020 and 2019, respectively. INCOME TAXES The Company has provided a valuation allowance on deferred income tax assets of approximately $3,522,000 and $3,175,000 as of August 31, 2020 and May 31, 2020, respectively.   FOREIGN CURRENCY TRANSLATION The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the quarters ended August 31, 2020 and 2019. RIGHT-OF-USE ASSETS AND LEASE LIABILITY The Company follows the guidance of ASC 842, Leases, which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.  Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. The Company leases office space and copy machines, all of which are operating leases. The Company has elected to exclude short-term leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.  The leases do not include the options to purchase the leased property.  The depreciable life of assets and leasehold improvements are limited by the expected lease term. NET LOSS PER SHARE Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per share calculation for the three months ended August 31, 2020 and 2019 was 1,925,750 and 1,416,584, respectively. The Company also has outstanding 321,429 of series A 5% convertible preferred stock, which may be converted at any time to common stock. RECENT ACCOUNTING PRONOUNCEMENTS Recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements. </div>

6758700

0.401

0.458

0.621

0.800

0.436

0.638

0.475

0.500

0.269

P90D

<div style="font-family: "Courier New"; font-size: 10pt; "> INVENTORIES The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. Inventories approximate the following at: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> <a name="OLE_LINK7"></a> </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" rowspan="2" valign="bottom">  August 31,2020</td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:13%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 13%; white-space: nowrap;" rowspan="2" valign="bottom"> May 31,2020</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Raw materials     </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2,219,000</td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:11%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 1,635,000</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:71%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 71%; white-space: nowrap;" valign="bottom"> Work in progress</td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 890,000</td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 988,000</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Finished products</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 992,000</td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 228,000</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 4,101,000</td> <td style="HEIGHT:15.75pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 2,851,000</td></tr></table> Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of August 31, 2020 and May 31, 2020, inventory reserves were approximately $72,000 and $67,000, respectively.</div>

72000

67000

P5Y

P10Y

26732

29498

P18Y

P10Y

P20Y

5838

5780

0.06

<div style="font-family: "Courier New"; font-size: 10pt; "> SHARE-BASED COMPENSATION The Company follows the guidance of the accounting provisions of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2020: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" rowspan="3" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" rowspan="4" valign="bottom"> Exercise Price Weighted Average</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%;" rowspan="2" valign="bottom"> Option Shares</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Outstanding May 31, 2020</td> <td style="HEIGHT:15.75pt; WIDTH:14%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 1,789,251</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2.75</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Granted</td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 171,000</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 7.46</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Exercised</td> <td style="HEIGHT:15pt; WIDTH:14%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> (12,500)</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.20</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Cancelled or expired</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> (22,001)</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3.43</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Outstanding August 31, 2020</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 1,925,750</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3.17</td></tr></table> During the three months ended August 31, 2020, options to purchase 12,500 shares of common stock were exercised at price of $1.20.  Total net proceeds to the Company were $14,900. During the three months ended August 31, 2020, the Company granted 171,000 options to purchase common stock at an average purchase price of $7.46.</div>

12500

1.20

14900

171000

7.46

<div style="font-family: "Courier New"; font-size: 10pt; "> REVENUE RECOGNITION The Company has various contracts with customers.  All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes.  The Company evaluated the status of these contracts as of August 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods.  Services for some contract work are invoiced and recognized for work that has been performed as the project progresses.  The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physician’s office products are sold to physicians and distributors, all of whom are categorized below according to the type of product sold to them.  The Company also manufactures certain components on a contract basis for domestic and international manufacturers. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom">  </td> <td colspan="5" style="HEIGHT:15pt; WIDTH:34%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 34%; white-space: nowrap;" valign="bottom"> Three Months Ended</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> August 31,2020</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16.24%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> August 31,2019</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4.24%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Clinical lab</td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 581,708</td> <td style="HEIGHT:15pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:4.24%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 890,152</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> OTC</td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 184,908</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:4.24%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 199,209</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Physician's office</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 197,331</td> <td style="HEIGHT:15pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:4.24%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 45,222</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Contract Manufacturing</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 179,859</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4.24%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 59,832</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:66%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:3%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,143,806</td> <td style="HEIGHT:15.75pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:4.24%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,194,415</td></tr></table> See Note 4 for additional information regarding revenue concentrations.</div>

3522000

3175000

1925750

1416584

321429

<table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> <a name="OLE_LINK7"></a> </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" rowspan="2" valign="bottom">  August 31,2020</td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:13%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 13%; white-space: nowrap;" rowspan="2" valign="bottom"> May 31,2020</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Raw materials     </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2,219,000</td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:11%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 1,635,000</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:71%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 71%; white-space: nowrap;" valign="bottom"> Work in progress</td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 890,000</td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:11%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 988,000</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Finished products</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 992,000</td> <td style="HEIGHT:15pt; WIDTH:1%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 228,000</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 4,101,000</td> <td style="HEIGHT:15.75pt; WIDTH:1%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 1%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 11%; white-space: nowrap;" valign="bottom"> 2,851,000</td></tr></table>

2219000

1635000

890000

988000

992000

228000

<table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" rowspan="3" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" rowspan="4" valign="bottom"> Exercise Price Weighted Average</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%;" rowspan="2" valign="bottom"> Option Shares</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Outstanding May 31, 2020</td> <td style="HEIGHT:15.75pt; WIDTH:14%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 1,789,251</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2.75</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Granted</td> <td style="HEIGHT:15pt; WIDTH:14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 171,000</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 7.46</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Exercised</td> <td style="HEIGHT:15pt; WIDTH:14%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> (12,500)</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.20</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Cancelled or expired</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> (22,001)</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3.43</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:70%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 70%; white-space: nowrap;" valign="bottom"> Outstanding August 31, 2020</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 14%; white-space: nowrap;" valign="bottom"> 1,925,750</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3.17</td></tr></table>

1789251

2.75

171000

7.46

1.20

22001

3.43

1925750

3.17

<table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom">  </td> <td colspan="5" style="HEIGHT:15pt; WIDTH:34%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 34%; white-space: nowrap;" valign="bottom"> Three Months Ended</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:15%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> August 31,2020</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16.24%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> August 31,2019</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4.24%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Clinical lab</td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 581,708</td> <td style="HEIGHT:15pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:4.24%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 890,152</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:69%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> OTC</td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 184,908</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:4.24%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 199,209</td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:69%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 69%; white-space: nowrap;" valign="bottom"> Physician's office</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 197,331</td> <td style="HEIGHT:15pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:4.24%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 45,222</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Contract Manufacturing</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:3%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 179,859</td> <td style="HEIGHT:15pt; WIDTH:2.76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:4.24%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 59,832</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:66%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 66%; white-space: nowrap;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:3%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,143,806</td> <td style="HEIGHT:15.75pt; WIDTH:2.76%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:4.24%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,194,415</td></tr></table>

581708

890152

184908

199209

197331

45222

179859

59832

1143806

1194415

<div style="font-family: "Courier New"; font-size: 10pt; "> NOTE 3:  SHAREHOLDERS’ EQUITY On July 20, 2020, the Company’s outstanding SEC Form S-3 “Shelf” registration statement dated July 20, 2017 expired. This prior registration statement registered an indeterminant number of shares equating to a maximum aggregate offering amount of $45,000,000 of shares. On July 21, 2020, the Company filed with the SEC a new Form S-3 “Shelf” registration statement to replace the registration statement that expired on July 20, 2020. The new registration statement registers common shares to be issued in a maximum aggregate amount of $90,000,000. Included in this registration statement was the registration of all of the common shares issued, or to be issued, to Palm Global Small Cap Master Fund LP upon conversion of their Series A 5% Convertible Preferred Stock into common shares. This S-3 registration statement became effective September 30, 2020. </div>

45000000

90000000

<div style="font-family: "Courier New"; font-size: 10pt; "> NOTE 4:  GEOGRAPHIC INFORMATION Financial information about foreign and domestic operations and export sales is approximately as follows: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="5" style="HEIGHT:15pt; WIDTH:30.32%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Three Months Ended</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14.32%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> August 31, 2020</td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14.32%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> August 31, 2019</td></tr> <tr style="HEIGHT:15pt"> <td colspan="3" style="HEIGHT:15pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;" valign="bottom"> Revenues from sales to unaffiliated customers:</td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> United States</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 134,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $ </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 115,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Asia</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 347,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 663,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Europe</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 591,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 301,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> South America</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 43,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 47,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Middle East</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 29,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 68,000 </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,144,000 </td> <td style="HEIGHT:15.75pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $ </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,194,000 </td></tr></table> As of August 31, 2020 and May 31, 2020, approximately $587,000 and $613,000 of Biomerica’s gross inventory and approximately $30,000 and $31,000, of Biomerica’s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively. </div>

587000

613000

30000

31000

<table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; ; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="5" style="HEIGHT:15pt; WIDTH:30.32%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Three Months Ended</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14.32%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> August 31, 2020</td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14.32%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> August 31, 2019</td></tr> <tr style="HEIGHT:15pt"> <td colspan="3" style="HEIGHT:15pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;" valign="bottom"> Revenues from sales to unaffiliated customers:</td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> United States</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 134,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $ </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 115,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Asia</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 347,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 663,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Europe</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 591,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 301,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> South America</td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 43,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.04%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12.28%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 47,000 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:69.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Middle East</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 29,000 </td> <td style="HEIGHT:15pt; WIDTH:1.68%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 68,000 </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:69.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,144,000 </td> <td style="HEIGHT:15.75pt; WIDTH:1.68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2.04%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $ </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12.28%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 1,194,000 </td></tr></table>

134000

115000

347000

663000

591000

301000

43000

47000

29000

68000

<div style="font-family: "Courier New"; font-size: 10pt; "> NOTE 5:  LEASES On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016.   In November 2015, the Company signed the First Amendment to extend the lease until August 31, 2021. As of September 1, 2020, the rent was $23,637 per month. In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The rent is currently $3,239 per month. The Company has one 10-year option to renew at the end of the initial lease period.  Biomerica, Inc. is not a guarantor of such lease. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office on a month-to-month basis in Lindau, Germany, as headquarters for BioEurope GmbH, its Germany subsidiary. Components of lease expense include fixed lease expense of $85,946 for the three months ended August 31, 2020.  For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company’s office and equipment leases generally have contractually specified minimum rent and annual rent increases which are included in the measurement of the right-of-use asset and related lease liability.  Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred.  <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:30pt"> <td style="HEIGHT:30pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Supplemental cash flow information related to leases for the three months ended August 31, 2020:  </td> <td style="HEIGHT:30pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:30pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:30pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:30pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Operating cash flows from operating leases      </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> 78,561</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Right-of-use assets obtained in exchange for   new operating lease liabilities</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> --</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Weighted average remaining lease term (in years)</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> 6.02</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Weighted average discount rate</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> 6.5</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> %</td></tr></table> The maturity of lease liabilities as of August 31, 2020 are as follows: <table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 86%; white-space: nowrap;" valign="bottom"> Fiscal Years ending May 31st:</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2021</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 161,927</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2022</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 236,391</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2023</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 262,810</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2024</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 291,328</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2025</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 322,098</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> Thereafter</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 457,053</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10.1pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 1,731,607</td></tr></table> </div>

23637

P10Y

3239

85946

2009-09-01

2016-08-31

2021-08-31

<table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:30pt"> <td style="HEIGHT:30pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Supplemental cash flow information related to leases for the three months ended August 31, 2020:  </td> <td style="HEIGHT:30pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:30pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:30pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:30pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Operating cash flows from operating leases      </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> 78,561</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Right-of-use assets obtained in exchange for   new operating lease liabilities</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> --</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Weighted average remaining lease term (in years)</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> 6.02</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:78%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 78%; white-space: nowrap;" valign="bottom"> Weighted average discount rate</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:3%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 3%; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:15%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 15%; white-space: nowrap;" valign="bottom"> 6.5</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> %</td></tr></table>

78561

P6Y7D

0.065

<table width="733" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 86%; white-space: nowrap;" valign="bottom"> Fiscal Years ending May 31st:</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2021</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 161,927</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2022</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 236,391</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2023</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 262,810</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2024</td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 291,328</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> 2025</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 322,098</td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> Thereafter</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 457,053</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:86%; BACKGROUND:#bdd7ee; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10.1pt; PADDING-RIGHT:0in; width: 86%;" valign="bottom"> Total</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#bdd7ee; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%;" valign="bottom"> 1,731,607</td></tr></table>

161927

236391

262810

291328

322098

457053

1731607

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> NOTE 6:  COMMITMENTS AND CONTINGENCIES Contracts and Licensing Agreements On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (“Telcon Agreement”) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (“Telcon”), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica’s new InFoods® IBS products (“IBS Products”) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the US FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final US FDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica’s starting clinical trials in the United States, receipt of US FDA clearance and Telcon’s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid. Additionally, the Telcon Agreement provides for a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon.  In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon’s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019. In September 2017, the Telcon Agreement was amended to extend the date by which Telcon must attain Korean FDA approval until April 30, 2020. During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021. On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica InFoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850. As disclosed in the Form 10K filed with the SEC on August 31, 2020, on July 2, 2020, the Company received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. The Company is continuing to cooperate fully with the SEC’s investigation and provide information as requested. At this time, the Company is unable to predict the duration, scope or outcome of this investigation. </div>

1250000

83333

250000

0.15 139850

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> NOTE 7:  SUBSEQUENT EVENTS On September 15, 2020, the Company entered into an agreement with Public Health England research institution for the purpose of evaluating the Company’s COVID-19 Rapid Test. On October 5, 2020, the Company entered into a sales agreement with a Ukrainian distributor. The agreement covers a four-year period and the total contract is valued at $480,000. </div>

480000

EX-101.SCH 7 bmra-20200831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Alternate 0 link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - GEOGRAPHIC INFORMATION link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - LEASES link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - LEASES (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - SHAREHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - GEOGRAPHIC INFORMATION (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - LEASES (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - LEASES (Details) - Supplemental cash flow information related to leases link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - LEASES (Details) - The maturity of lease liabilities link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 bmra-20200831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bmra-20200831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bmra-20200831_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Income Statement [Abstract] Net sales Cost of sales Gross Profit Selling, general and administrative Research and development Research and Development Expense Total operating expense Loss from operations Dividend and interest income Total other income Loss before income taxes Provision for income taxes Net loss Net loss Net loss Basic net loss per common share (in Dollars per share) Diluted net loss per common share (in Dollars per share) Basic (in Shares) Diluted (in Shares) Foreign currency translation Comprehensive loss Statement of Financial Position [Abstract] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts receivable, less allowance for doubtful accounts of $272,356 and $70,981 as of August 31, 2020 and May 31, 2020, respectively Allowance for doubtful accounts (in Dollars) Inventories, net Total Prepaid expenses and other Total current assets Property and Equipment, net of accumulated depreciation and amortization of $1,894,375 and $1,867,643 as of August 31, 2020 and May 31, 2020, respectively Property, Plant and Equipment, Net Accumulated depreciation and amortization (in Dollars) Right of Use Assets, net of accumulated amortization of $288,746 and $231,489 as of August 31, 2020 and May 31, 2020, respectively Accumulated amortization, Right of Use Assets (in Dollars) Investments Intangible Assets, net of accumulated amortization of $501,962 and $496,124 as of August 31, 2020 and May 31, 2020, respectively Accumulated amortization, Intangible Assets (in Dollars) Other Assets Total Assets Accounts payable and accrued expenses Accrued compensation Lease liability, current portion Total current liabilities Lease Liability, net of current portion Total Liabilities Commitments and Contingencies (Notes 5 and 6) Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020 and Preferred stock, undesignated, no par value,4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020 Equity Interest Type [Axis] Class of Stock [Axis] Preferred Stock, Par Value (in Dollars per share) Preferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Preferred Stock, No Par Value (in Dollars per share) Preferred Stock, undesignated shares Common stock, $0.08 par value, 25,000,000 shares authorized, 11,752,589 and 11,740,089 issued and outstanding at August 31, 2020 and May 31, 2020, respectively Common stock par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in-capital Accumulated other comprehensive loss Accumulated deficit Total Shareholders' Equity Balances Balances Total Liabilities and Shareholders' Equity Statement of Stockholders' Equity [Abstract] Balances (in Shares) Balances (in Shares) Exercise of stock options Exercise of stock options (in Shares) Option Exercised, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) Compensation expense in connection with options granted Equity Components [Axis] Statement of Cash Flows [Abstract] Depreciation and amortization Change in provision for allowance on accounts receivable Inventory reserve Stock option expense Reduction in deferred rent liability Amortization of right-of-use asset Accounts receivable Inventories Prepaid expenses and other assets Reduction in lease liability Other assets Accounts payable and accrued expenses Accrued compensation Net cash used in operating activities Increase in intangibles Purchases of property and equipment Net cash used in investing activities Proceeds from sale of common stock, net Proceeds from Issuance of Common Stock Proceeds from exercise of stock options Proceeds from Stock Options Exercised Net cash provided by financing activities Effect of exchange rate changes in cash Net (decrease) increase in cash and cash equivalents Interest Income taxes Establishment of Right-Of-Use Asset per ASC 842 Establishment of Lease Liability per ASC 842 Accounting Policies [Abstract] Inventories [Abstract] Raw materials Work in progress Finished products Options Activity [Abstract] Options Outstanding, Shares Options Outstanding, Shares Option Outstanding, Exercise Price Weighted Average Option Outstanding, Exercise Price Weighted Average Option Granted, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) Option Granted, Exercise Price Weighted Average Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) Option Exercised, Exercise Price Weighted Average Option Cancelled or expired, Shares Option Cancelled or expired, Exercise Price Weighted Average Award Type [Axis] Revenue from contracts with customers [Abstract] Segments [Axis] Revenue From Customers Stockholders' Equity Note [Abstract] Geographic Information Disclosure [Abstract] Geographic information regarding net sales [Abstract] Geographical [Axis] Disclosure Text Block [Abstract] Supplemental cash flow information related to leases [Abstract] Operating cash flows from operating leases Right-of-use assets obtained in exchange for new operating lease liabilities Weighted average remaining lease term (in years) Weighted average discount rate The maturity of lease liabilities [Abstract] 2021 2022 2023 2024 2025 Thereafter Total Commitments and Contingencies Disclosure [Abstract] Subsequent Events [Abstract] Document Period End Date Entity Registrant Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Shell Company Entity Common Stock, Shares Outstanding Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Type Entity Central Index Key Entity Emerging Growth Company Operating Expenses: Other Income: Weighted average number of common and common equivalent shares: Other comprehensive loss, net of tax: The accompanying notes are an integral part of these statements. Assets Current Assets: The accompanying notes are an integral part of these statements. Current Liabilities: Shareholders' Equity: The accompanying notes are an integral part of these statements. The accompanying notes are an integral part of these statements. Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Changes in assets and liabilities: Cash flows from investing activities: Cash flows from financing activities: Supplemental Disclosure of Cash-Flow Information: Cash paid during the period for: Non-cash investing and financing activities: The accompanying notes are an integral part of these statements. 5% Convertible Preferred Stock [Member] Series A Preferred Stock [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Basis of Accounting [Text Block] Significant Accounting Policies [Text Block] Schedule of Inventory, Current [Table Text Block] Share-based Payment Arrangement, Option, Activity [Table Text Block] Disaggregation of Revenue [Table Text Block] Stockholders' Equity Note Disclosure [Text Block] Geographic Information Disclosure [Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Revenues from sales to unaffiliated customers: Lessee, Operating Leases [Text Block] Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block] EX-101.PRE 11 bmra-20200831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Aug. 31, 2020	Oct. 15, 2020
Document Information Line Items
Entity Registrant Name	BIOMERICA INC
Document Type	10-Q
Current Fiscal Year End Date	--05-31
Entity Common Stock, Shares Outstanding		11,752,589
Amendment Flag	false
Entity Central Index Key	0000073290
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Aug. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Income Statement [Abstract]
Net sales	$ 1,143,806	$ 1,194,415
Cost of sales	(960,930)	(827,111)
Gross Profit	182,876	367,304
Operating Expenses:
Selling, general and administrative	1,164,564	506,397
Research and development	674,693	370,466
Total operating expense	1,839,257	876,863
Loss from operations	(1,656,381)	(509,559)
Other Income:
Dividend and interest income	8,091	4,063
Total other income	8,091	4,063
Loss before income taxes	(1,648,290)	(505,496)
Provision for income taxes	1,125	800
Net loss	$ (1,649,415)	$ (506,296)
Basic net loss per common share (in Dollars per share)	$ (0.14)	$ (0.05)
Diluted net loss per common share (in Dollars per share)	$ (0.14)	$ (0.05)
Weighted average number of common and common equivalent shares:
Basic (in Shares)	11,748,377	9,744,461
Diluted (in Shares)	11,748,377	9,744,461
Net loss	$ (1,649,415)	$ (506,296)
Other comprehensive loss, net of tax:
Foreign currency translation	(1,721)	(3,442)
Comprehensive loss	$ (1,651,136)	$ (509,738)

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Aug. 31, 2020	May 31, 2020
Current Assets:
Cash and cash equivalents	$ 6,964,314	$ 8,641,027
Accounts receivable, less allowance for doubtful accounts of $272,356 and $70,981 as of August 31, 2020 and May 31, 2020, respectively	1,583,420	1,765,871
Inventories, net	4,101,404	2,850,836
Prepaid expenses and other	470,934	1,509,083
Total current assets	13,120,072	14,766,817
Property and Equipment, net of accumulated depreciation and amortization of $1,894,375 and $1,867,643 as of August 31, 2020 and May 31, 2020, respectively	292,235	279,379
Right of Use Assets, net of accumulated amortization of $288,746 and $231,489 as of August 31, 2020 and May 31, 2020, respectively	1,654,253	1,711,510
Investments	165,324	165,324
Intangible Assets, net of accumulated amortization of $501,962 and $496,124 as of August 31, 2020 and May 31, 2020, respectively	215,975	168,655
Other Assets	444,631	168,193
Total Assets	15,892,490	17,259,878
Current Liabilities:
Accounts payable and accrued expenses	1,270,913	986,711
Accrued compensation	309,345	278,627
Lease liability, current portion	221,201	211,809
Total current liabilities	1,801,459	1,477,147
Lease Liability, net of current portion	1,510,406	1,569,678
Total Liabilities	3,311,865	3,046,825
Commitments and Contingencies (Notes 5 and 6)
Shareholders' Equity:
Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020 and Preferred stock, undesignated, no par value,4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020	25,714	25,714
Common stock, $0.08 par value, 25,000,000 shares authorized, 11,752,589 and 11,740,089 issued and outstanding at August 31, 2020 and May 31, 2020, respectively	940,205	939,205
Additional paid-in-capital	35,231,415	35,213,707
Accumulated other comprehensive loss	(41,562)	(39,841)
Accumulated deficit	(23,575,147)	(21,925,732)
Total Shareholders' Equity	12,580,625	14,213,053
Total Liabilities and Shareholders' Equity	15,892,490	17,259,878
5% Convertible Preferred Stock [Member] \| Series A Preferred Stock [Member]
Shareholders' Equity:
Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020 and Preferred stock, undesignated, no par value,4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020	25,714	25,714
Preferred Stock [Member]
Shareholders' Equity:
Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at August 31, 2020 and May 31, 2020 and Preferred stock, undesignated, no par value,4,428,571 shares authorized, none issued and outstanding at August 31, 2020 and May 31, 2020

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Aug. 31, 2020	May 31, 2020
Allowance for doubtful accounts (in Dollars)	$ 272,356	$ 70,981
Accumulated depreciation and amortization (in Dollars)	1,894,375	1,867,643
Accumulated amortization, Right of Use Assets (in Dollars)	288,746	231,489
Accumulated amortization, Intangible Assets (in Dollars)	$ 501,962	$ 496,124
Common stock par value (in Dollars per share)	$ 0.08	$ 0.08
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	11,752,589	11,740,089
Common stock, shares outstanding	11,752,589	11,740,089
5% Convertible Preferred Stock [Member] \| Series A Preferred Stock [Member]
Preferred Stock, Par Value (in Dollars per share)	$ 0.08	$ 0.08
Preferred Stock, shares authorized	571,429	571,429
Preferred Stock, shares issued	321,429	321,429
Preferred Stock, shares outstanding	321,429	321,429
Preferred Stock [Member]
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Preferred Stock, No Par Value (in Dollars per share)	$ 0	$ 0
Preferred Stock, undesignated shares	4,428,571	4,428,571

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited) - 3 months ended Aug. 31, 2020 - USD ($)	Series A Preferred Stock [Member] 5% Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balances at May. 31, 2020	$ 25,714	$ 939,205	$ 35,213,707	$ (39,841)	$ (21,925,732)	$ 14,213,053
Balances (in Shares) at May. 31, 2020	321,429	11,740,089
Exercise of stock options		$ 1,000	13,900			14,900
Exercise of stock options (in Shares)		12,500
Foreign currency translation				(1,721)		(1,721)
Compensation expense in connection with options granted			3,808			3,808
Net loss					(1,649,415)	(1,649,415)
Balances at Aug. 31, 2020	$ 25,714	$ 940,205	$ 35,231,415	$ (41,562)	$ (23,575,147)	$ 12,580,625
Balances (in Shares) at Aug. 31, 2020	321,429	11,752,589

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,649,415)	$ (506,296)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	32,570	35,278
Change in provision for allowance on accounts receivable	201,375	(6,967)
Inventory reserve	5,005	2,320
Stock option expense	3,808	5,850
Reduction in deferred rent liability		(37,971)
Amortization of right-of-use asset	57,257	102,456
Changes in assets and liabilities:
Accounts receivable	(18,924)	603,107
Inventories	(1,255,573)	(57,568)
Prepaid expenses and other assets	1,038,149	(41,165)
Reduction in lease liability	(49,880)	(54,796)
Other assets	(276,438)
Accounts payable and accrued expenses	284,202	(55,718)
Accrued compensation	30,718	3,316
Net cash used in operating activities	(1,597,146)	(8,154)
Cash flows from investing activities:
Increase in intangibles	(53,158)	(12,100)
Purchases of property and equipment	(39,588)	(2,171)
Net cash used in investing activities	(92,746)	(14,271)
Cash flows from financing activities:
Proceeds from sale of common stock, net		112,608
Proceeds from exercise of stock options	14,900	34,028
Net cash provided by financing activities	14,900	146,636
Effect of exchange rate changes in cash	(1,721)	(3,442)
Net (decrease) increase in cash and cash equivalents	(1,676,713)	120,769
Cash and cash equivalents at beginning of period	8,641,027	686,785
Cash and cash equivalents at end of period	6,964,314	807,554
Cash paid during the period for:
Interest
Income taxes	1,125
Non-cash investing and financing activities:
Establishment of Right-Of-Use Asset per ASC 842		1,942,999
Establishment of Lease Liability per ASC 842		$ 1,980,970

XML 18 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Aug. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	NOTE 1: BASIS OF PRESENTATION Biomerica, Inc. and Subsidiaries (collectively "the Company") are primarily engaged in the development, manufacture and marketing of medical diagnostic products. The Company develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and other medical conditions. The Company’s medical diagnostic products are sold worldwide in two markets: 1) clinical laboratories and 2) point of care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. The information set forth in these condensed consolidated financial statements is unaudited and reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc. and subsidiaries, for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. All adjustments that were made are of a normal recurring nature. The unaudited, Condensed Consolidated Financial Statements and notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in our annual financial statements and notes. The condensed consolidated balance sheet data as of May 31, 2020 was derived from audited financial statements. The accompanying interim condensed consolidated financial statements should be read in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on August 31, 2020 for the fiscal year ended May 31, 2020. The results of operations for our interim periods are not necessarily indicative of results to be achieved for our full fiscal year.

XML 19 R8.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Aug. 31, 2020

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 2:  SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. 

ACCOUNTING ESTIMATES

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based information). Actual results could materially differ from those estimates. 

CONCENTRATION OF CREDIT RISK

The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.  As of August 31, 2020, the Company had approximately $6,758,700 of uninsured cash.  The Company does not believe it is exposed to significant credit risks.

For the quarters ended August 31, 2020 and August 31, 2019, the Company had two distributors and one distributor which accounted for 40.1% and 45.8% of net consolidated sales, respectively.  At August 31, 2020 and May 31, 2020 the Company had two distributors and three distributors which accounted for a total of 62.1% and 80.0%, respectively, of gross accounts receivable.  Of the 62.1% as of August 31, 2020, 43.6% was owed by a distributor in South America.  

For the quarters ended August 31, 2020 and 2019, two vendors accounted for approximately 63.8% and two vendors which accounted for 47.5% of the purchases or raw materials, respectively. As of August 31, 2020 and May 31, 2020 the Company had 3 vendors and 2 vendors which accounted for 50.0% and 26.9%, respectively, of accounts payable.

CASH AND CASH EQUIVALENTS 

Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.

ACCOUNTS RECEIVABLE

The Company extends unsecured credit to its customers located throughout the United States and the world. International accounts are normally required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.  Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper level management.  Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. For receivables over ninety days old, the Company begins to reserve a portion of the balance unless collection is reasonably assured.   

Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables.   Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.

INVENTORIES 

The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.

Inventories approximate the following at:

   
  August 31,2020
  May 31,2020
  
      
 Raw materials     
 $
 2,219,000
  
 $
 1,635,000
 Work in progress
 890,000
   988,000
 Finished products
  
 992,000
  
  
 228,000
 Total
 $
 4,101,000
  $
 2,851,000

Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of August 31, 2020 and May 31, 2020, inventory reserves were approximately $72,000 and $67,000, respectively.

PROPERTY AND EQUIPMENT, NET

Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. 

Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $26,732 and $29,498 for the three months ended August 31, 2020 and 2019, respectively.

INTANGIBLES ASSETS, NET

Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $5,838 and $5,780 for the three months ended August 31, 2020 and 2019, respectively. 

The Company assesses the recoverability of these intangible assets by determining whether the amortization of the assets balances over its remaining life can be recovered through projected undiscounted future cash flows.  The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of August 31, 2020 or 2019.

INVESTMENTS

From time-to-time, the Company makes investments in privately-held companies.  The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable.  If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices.  The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be greater than the fair value.  The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment.  Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.

SHARE-BASED COMPENSATION

The Company follows the guidance of the accounting provisions of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.

The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2020:

     Exercise
Price
Weighted
Average
  
  Option Shares
  
 Outstanding May 31, 2020
 1,789,251
  
 $
 2.75
 Granted
 171,000
   7.46
 Exercised
 (12,500)
  
  
 1.20
 Cancelled or expired
 (22,001)
   
 3.43
 Outstanding August 31, 2020
 1,925,750
  
 $
 3.17

During the three months ended August 31, 2020, options to purchase 12,500 shares of common stock were exercised at price of $1.20.  Total net proceeds to the Company were $14,900.

During the three months ended August 31, 2020, the Company granted 171,000 options to purchase common stock at an average purchase price of $7.46.

REVENUE RECOGNITION

The Company has various contracts with customers.  All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes.  The Company evaluated the status of these contracts as of August 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods.  Services for some contract work are invoiced and recognized for work that has been performed as the project progresses.  The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physician’s office products are sold to physicians and distributors, all of whom are categorized below according to the type of product sold to them.  The Company also manufactures certain components on a contract basis for domestic and international manufacturers.

Disaggregation of revenue:

The following is a breakdown of revenues according to markets to which the products are sold:

   
 Three Months Ended
  
 August 31,2020
  
 August 31,2019
      
 Clinical lab
 $
 581,708
  
 $
 890,152
 OTC
 184,908
   199,209
 Physician's office
 197,331
  
  
 45,222
 Contract Manufacturing
  
 179,859
  
  
 59,832
 Total
 $
 1,143,806
  $
 1,194,415

See Note 4 for additional information regarding revenue concentrations.

SHIPPING AND HANDLING FEES

The Company includes shipping and handling fees billed to customers in net sales.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred.  The Company expensed $674,693 and $370,466 of research and development costs during the quarters ended August 31, 2020 and 2019, respectively.

INCOME TAXES

The Company has provided a valuation allowance on deferred income tax assets of approximately $3,522,000 and $3,175,000 as of August 31, 2020 and May 31, 2020, respectively.   

FOREIGN CURRENCY TRANSLATION

The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the quarters ended August 31, 2020 and 2019.

RIGHT-OF-USE ASSETS AND LEASE LIABILITY

The Company follows the guidance of ASC 842, Leases, which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.  Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. The Company leases office space and copy machines, all of which are operating leases. The Company has elected to exclude short-term leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.  The leases do not include the options to purchase the leased property.  The depreciable life of assets and leasehold improvements are limited by the expected lease term.

NET LOSS PER SHARE

Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per share calculation for the three months ended August 31, 2020 and 2019 was 1,925,750 and 1,416,584, respectively. The Company also has outstanding 321,429 of series A 5% convertible preferred stock, which may be converted at any time to common stock.

RECENT ACCOUNTING PRONOUNCEMENTS

Recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements. 

XML 20 R9.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY	3 Months Ended
SHAREHOLDERS' EQUITY	Aug. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 3: SHAREHOLDERS’ EQUITY On July 20, 2020, the Company’s outstanding SEC Form S-3 “Shelf” registration statement dated July 20, 2017 expired. This prior registration statement registered an indeterminant number of shares equating to a maximum aggregate offering amount of $45,000,000 of shares. On July 21, 2020, the Company filed with the SEC a new Form S-3 “Shelf” registration statement to replace the registration statement that expired on July 20, 2020. The new registration statement registers common shares to be issued in a maximum aggregate amount of $90,000,000. Included in this registration statement was the registration of all of the common shares issued, or to be issued, to Palm Global Small Cap Master Fund LP upon conversion of their Series A 5% Convertible Preferred Stock into common shares. This S-3 registration statement became effective September 30, 2020.

XML 21 R10.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC INFORMATION

3 Months Ended

Aug. 31, 2020

Geographic Information Disclosure [Abstract]

Geographic Information Disclosure [Text Block]

NOTE 4:  GEOGRAPHIC INFORMATION

Financial information about foreign and domestic operations and export sales is approximately as follows:

 Three Months Ended
  
 August 31, 2020
  
 August 31, 2019
 Revenues from sales to unaffiliated customers:
  
 United States
 $
 134,000 
  
 $ 
 115,000 
 Asia
  
 347,000 
  
 663,000 
 Europe
  
 591,000 
  
 301,000 
 South America
  
 43,000 
  
 47,000 
 Middle East
  
 29,000 
  
 68,000 
  
 $
 1,144,000 
  
 $ 
 1,194,000 

As of August 31, 2020 and May 31, 2020, approximately $587,000 and $613,000 of Biomerica’s gross inventory and approximately $30,000 and $31,000, of Biomerica’s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

LEASES

3 Months Ended

Aug. 31, 2020

Disclosure Text Block [Abstract]

Lessee, Operating Leases [Text Block]

NOTE 5:  LEASES

On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016.   In November 2015, the Company signed the First Amendment to extend the lease until August 31, 2021. As of September 1, 2020, the rent was $23,637 per month.

In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The rent is currently $3,239 per month. The Company has one 10-year option to renew at the end of the initial lease period.  Biomerica, Inc. is not a guarantor of such lease. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office on a month-to-month basis in Lindau, Germany, as headquarters for BioEurope GmbH, its Germany subsidiary. 

Components of lease expense include fixed lease expense of $85,946 for the three months ended August 31, 2020.  For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company’s office and equipment leases generally have contractually specified minimum rent and annual rent increases which are included in the measurement of the right-of-use asset and related lease liability.  Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred.  

  Supplemental cash flow information related to leases for 
the three months ended August 31, 2020:  
    
     
 Operating cash flows from operating leases      
  $
 78,561
 
     
 Right-of-use assets obtained in exchange for 
  new operating lease liabilities
   --
 
 Weighted average remaining lease term (in years)
   6.02
 
 Weighted average discount rate
   6.5
 %

The maturity of lease liabilities as of August 31, 2020 are as follows:

  Fiscal Years ending May 31st:
  
 2021
 $
 161,927
 2022
  236,391
 2023
  
 262,810
 2024
  291,328
 2025
  
 322,098
 Thereafter
  
 457,053
 Total
 $
 1,731,607

XML 23 R12.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Aug. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 6: COMMITMENTS AND CONTINGENCIES Contracts and Licensing Agreements On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (“Telcon Agreement”) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (“Telcon”), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica’s new InFoods® IBS products (“IBS Products”) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the US FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final US FDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica’s starting clinical trials in the United States, receipt of US FDA clearance and Telcon’s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid. Additionally, the Telcon Agreement provides for a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon. In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon’s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019. In September 2017, the Telcon Agreement was amended to extend the date by which Telcon must attain Korean FDA approval until April 30, 2020. During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021. On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica InFoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850. As disclosed in the Form 10K filed with the SEC on August 31, 2020, on July 2, 2020, the Company received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. The Company is continuing to cooperate fully with the SEC’s investigation and provide information as requested. At this time, the Company is unable to predict the duration, scope or outcome of this investigation.

XML 24 R13.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Aug. 31, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 7: SUBSEQUENT EVENTS On September 15, 2020, the Company entered into an agreement with Public Health England research institution for the purpose of evaluating the Company’s COVID-19 Rapid Test. On October 5, 2020, the Company entered into a sales agreement with a Ukrainian distributor. The agreement covers a four-year period and the total contract is valued at $480,000.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

3 Months Ended

Aug. 31, 2020

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

PRINCIPLES OF CONSOLIDATION

The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]

ACCOUNTING ESTIMATES

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based information). Actual results could materially differ from those estimates.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

CONCENTRATION OF CREDIT RISK

The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies.  As of August 31, 2020, the Company had approximately $6,758,700 of uninsured cash.  The Company does not believe it is exposed to significant credit risks.

For the quarters ended August 31, 2020 and August 31, 2019, the Company had two distributors and one distributor which accounted for 40.1% and 45.8% of net consolidated sales, respectively.  At August 31, 2020 and May 31, 2020 the Company had two distributors and three distributors which accounted for a total of 62.1% and 80.0%, respectively, of gross accounts receivable.  Of the 62.1% as of August 31, 2020, 43.6% was owed by a distributor in South America.  

For the quarters ended August 31, 2020 and 2019, two vendors accounted for approximately 63.8% and two vendors which accounted for 47.5% of the purchases or raw materials, respectively. As of August 31, 2020 and May 31, 2020 the Company had 3 vendors and 2 vendors which accounted for 50.0% and 26.9%, respectively, of accounts payable.

Cash and Cash Equivalents, Policy [Policy Text Block]

CASH AND CASH EQUIVALENTS 

Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.

Accounts Receivable [Policy Text Block]

ACCOUNTS RECEIVABLE

The Company extends unsecured credit to its customers located throughout the United States and the world. International accounts are normally required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria.  Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper level management.  Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. For receivables over ninety days old, the Company begins to reserve a portion of the balance unless collection is reasonably assured.   

Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables.   Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.

Inventory, Policy [Policy Text Block]

INVENTORIES 

The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities.

Inventories approximate the following at:

   
  August 31,2020
  May 31,2020
  
      
 Raw materials     
 $
 2,219,000
  
 $
 1,635,000
 Work in progress
 890,000
   988,000
 Finished products
  
 992,000
  
  
 228,000
 Total
 $
 4,101,000
  $
 2,851,000

Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of August 31, 2020 and May 31, 2020, inventory reserves were approximately $72,000 and $67,000, respectively.

Property, Plant and Equipment, Policy [Policy Text Block]

PROPERTY AND EQUIPMENT, NET

Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. 

Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $26,732 and $29,498 for the three months ended August 31, 2020 and 2019, respectively.

Goodwill and Intangible Assets, Policy [Policy Text Block]

INTANGIBLES ASSETS, NET

Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $5,838 and $5,780 for the three months ended August 31, 2020 and 2019, respectively. 

The Company assesses the recoverability of these intangible assets by determining whether the amortization of the assets balances over its remaining life can be recovered through projected undiscounted future cash flows.  The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of August 31, 2020 or 2019.

Investment, Policy [Policy Text Block]

INVESTMENTS

From time-to-time, the Company makes investments in privately-held companies.  The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable.  If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices.  The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be greater than the fair value.  The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment.  Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.

Share-based Payment Arrangement [Policy Text Block]

SHARE-BASED COMPENSATION

The Company follows the guidance of the accounting provisions of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.

The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2020:

     Exercise
Price
Weighted
Average
  
  Option Shares
  
 Outstanding May 31, 2020
 1,789,251
  
 $
 2.75
 Granted
 171,000
   7.46
 Exercised
 (12,500)
  
  
 1.20
 Cancelled or expired
 (22,001)
   
 3.43
 Outstanding August 31, 2020
 1,925,750
  
 $
 3.17

During the three months ended August 31, 2020, options to purchase 12,500 shares of common stock were exercised at price of $1.20.  Total net proceeds to the Company were $14,900.

During the three months ended August 31, 2020, the Company granted 171,000 options to purchase common stock at an average purchase price of $7.46.

Revenue [Policy Text Block]

REVENUE RECOGNITION

The Company has various contracts with customers.  All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes.  The Company evaluated the status of these contracts as of August 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods.  Services for some contract work are invoiced and recognized for work that has been performed as the project progresses.  The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physician’s office products are sold to physicians and distributors, all of whom are categorized below according to the type of product sold to them.  The Company also manufactures certain components on a contract basis for domestic and international manufacturers.

Disaggregation of revenue:

The following is a breakdown of revenues according to markets to which the products are sold:

   
 Three Months Ended
  
 August 31,2020
  
 August 31,2019
      
 Clinical lab
 $
 581,708
  
 $
 890,152
 OTC
 184,908
   199,209
 Physician's office
 197,331
  
  
 45,222
 Contract Manufacturing
  
 179,859
  
  
 59,832
 Total
 $
 1,143,806
  $
 1,194,415

See Note 4 for additional information regarding revenue concentrations.

Cost of Goods and Service [Policy Text Block]

SHIPPING AND HANDLING FEES

The Company includes shipping and handling fees billed to customers in net sales.

Research and Development Expense, Policy [Policy Text Block]

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred.  The Company expensed $674,693 and $370,466 of research and development costs during the quarters ended August 31, 2020 and 2019, respectively.

Income Tax, Policy [Policy Text Block]

INCOME TAXES

The Company has provided a valuation allowance on deferred income tax assets of approximately $3,522,000 and $3,175,000 as of August 31, 2020 and May 31, 2020, respectively.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

FOREIGN CURRENCY TRANSLATION

The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the quarters ended August 31, 2020 and 2019.

Lessee, Leases [Policy Text Block]

RIGHT-OF-USE ASSETS AND LEASE LIABILITY

The Company follows the guidance of ASC 842, Leases, which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset.  Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. The Company leases office space and copy machines, all of which are operating leases. The Company has elected to exclude short-term leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.  The leases do not include the options to purchase the leased property.  The depreciable life of assets and leasehold improvements are limited by the expected lease term.

Earnings Per Share, Policy [Policy Text Block]

NET LOSS PER SHARE

Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per share calculation for the three months ended August 31, 2020 and 2019 was 1,925,750 and 1,416,584, respectively. The Company also has outstanding 321,429 of series A 5% convertible preferred stock, which may be converted at any time to common stock.

New Accounting Pronouncements, Policy [Policy Text Block]

RECENT ACCOUNTING PRONOUNCEMENTS

Recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

XML 26 R15.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Aug. 31, 2020

Accounting Policies [Abstract]

Schedule of Inventory, Current [Table Text Block]

	August 31,2020		May 31,2020
	August 31,2020		May 31,2020

Raw materials	$	2,219,000	$	1,635,000
Work in progress		890,000		988,000
Finished products		992,000		228,000
Total	$	4,101,000	$	2,851,000

Share-based Payment Arrangement, Option, Activity [Table Text Block]

		Exercise Price Weighted Average

	Option Shares
	Option Shares
Outstanding May 31, 2020	1,789,251	$	2.75
Granted	171,000		7.46
Exercised	(12,500)		1.20
Cancelled or expired	(22,001)		3.43
Outstanding August 31, 2020	1,925,750	$	3.17

Disaggregation of Revenue [Table Text Block]

	Three Months Ended
	August 31,2020		August 31,2019

Clinical lab	$	581,708	$	890,152
OTC		184,908		199,209
Physician's office		197,331		45,222
Contract Manufacturing		179,859		59,832
Total	$	1,143,806	$	1,194,415

XML 27 R16.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC INFORMATION (Tables)

3 Months Ended

Aug. 31, 2020

Geographic Information Disclosure [Abstract]

Revenue from External Customers by Geographic Areas [Table Text Block]

	Three Months Ended
	August 31, 2020		August 31, 2019
Revenues from sales to unaffiliated customers:
United States	$	134,000	$	115,000
Asia		347,000		663,000
Europe		591,000		301,000
South America		43,000		47,000
Middle East		29,000		68,000
	$	1,144,000	$	1,194,000

XML 28 R17.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

3 Months Ended

Aug. 31, 2020

Disclosure Text Block [Abstract]

Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]

Supplemental cash flow information related to leases for the three months ended August 31, 2020:

Operating cash flows from operating leases	$	78,561

Right-of-use assets obtained in exchange for new operating lease liabilities		--
Weighted average remaining lease term (in years)		6.02
Weighted average discount rate		6.5	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Fiscal Years ending May 31st:
2021	$	161,927
2022		236,391
2023		262,810
2024		291,328
2025		322,098
Thereafter		457,053
Total	$	1,731,607

XML 29 R18.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)		3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	May 31, 2020	Aug. 31, 2020	Aug. 31, 2019
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, Uninsured Amount		$ 6,758,700
Threshold Period Past Due for Write-off of Trade Accounts Receivable		90 days
Inventory Valuation Reserves	$ 67,000	$ 72,000
Depreciation, Depletion and Amortization		26,732	$ 29,498
Amortization of Intangible Assets		$ 5,838	5,780
Equity Method Investment, Ownership Percentage		6.00%
Proceeds from Stock Options Exercised		$ 14,900	34,028
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)		171,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)		$ 7.46
Research and Development Expense		$ 674,693	370,466
Deferred Tax Assets, Valuation Allowance	$ 3,175,000		$ 3,522,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)		1,925,750	1,416,584
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)		321,429
Minimum [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life		5 years
Maximum [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life		10 years
Distribution Rights [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		18 years
Purchased Technology Rights [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		10 years
Patents [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life		20 years
Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		40.10%	45.80%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	80.00%	62.10%
Customer Concentration Risk [Member] \| South America [Member] \| Accounts Receivable [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		43.60%
Supplier Concentration Risk [Member] \| Cost of Goods and Service, Product and Service Benchmark [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		63.80%	47.50%
Supplier Concentration Risk [Member] \| Accounts Payable [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	26.90%	50.00%
Share-based Payment Arrangement, Option [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)		12,500
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 1.20
Proceeds from Stock Options Exercised		$ 14,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)		171,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)		$ 7.46

XML 30 R19.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories - USD ($)	Aug. 31, 2020	May 31, 2020
Inventories [Abstract]
Raw materials	$ 2,219,000	$ 1,635,000
Work in progress	890,000	988,000
Finished products	992,000	228,000
Total	$ 4,101,404	$ 2,850,836

XML 31 R20.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity - Share-based Payment Arrangement, Option [Member]	3 Months Ended
	Aug. 31, 2020 $ / shares shares
SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity [Line Items]
Options Outstanding, Shares \| shares	1,789,251
Option Outstanding, Exercise Price Weighted Average \| $ / shares	$ 2.75
Option Granted, Shares \| shares	171,000
Option Granted, Exercise Price Weighted Average \| $ / shares	$ 7.46
Option Exercised, Shares \| shares	(12,500)
Option Exercised, Exercise Price Weighted Average \| $ / shares	$ 1.20
Option Cancelled or expired, Shares \| shares	(22,001)
Option Cancelled or expired, Exercise Price Weighted Average \| $ / shares	$ 3.43
Options Outstanding, Shares \| shares	1,925,750
Option Outstanding, Exercise Price Weighted Average \| $ / shares	$ 3.17

XML 32 R21.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers - USD ($)	3 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue From Customers	$ 1,143,806	$ 1,194,415
Clinical Lab [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	581,708	890,152
OTC [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	184,908	199,209
Physicians Office [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	197,331	45,222
Contract Manufacturing [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	$ 179,859	$ 59,832

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Details) - USD ($)	Jul. 21, 2020	Jul. 20, 2020
Common Stock [Member] \| Maximum [Member]
SHAREHOLDERS' EQUITY (Details) [Line Items]
Proceeds from Issuance of Common Stock	$ 90,000,000	$ 45,000,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC INFORMATION (Details) - MEXICO - USD ($)	Aug. 31, 2020	May 31, 2020
GEOGRAPHIC INFORMATION (Details) [Line Items]
Inventory, Gross	$ 587,000	$ 613,000
Property, Plant and Equipment, Net	$ 30,000	$ 31,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales - USD ($)	3 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	$ 1,143,806	$ 1,194,415
UNITED STATES
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	134,000	115,000
Asia [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	347,000	663,000
Europe [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	591,000	301,000
South America [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	43,000	47,000
Middle East [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	$ 29,000	$ 68,000

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

LEASES (Details) - USD ($)		1 Months Ended	3 Months Ended
LEASES (Details) - USD ($)	Jun. 18, 2009	Nov. 30, 2016	Aug. 31, 2020
LEASES (Details) [Line Items]
Operating Leases, Rent Expense			$ 85,946
Building In Irvine California [Member]
LEASES (Details) [Line Items]
Operating Leases, Rent Expense	$ 23,637
Operating Lease Initiation Date	Sep. 01, 2009
Lease Expiration Date	Aug. 31, 2016
Building In Irvine California [Member] \| First Amendment To Lease [Member]
LEASES (Details) [Line Items]
Lease Expiration Date	Aug. 31, 2021
MEXICO \| Property Available for Operating Lease [Member]
LEASES (Details) [Line Items]
Operating Leases, Rent Expense		$ 3,239
Lease Expiration Period		10 years

XML 37 R26.htm IDEA: XBRL DOCUMENT

LEASES (Details) - Supplemental cash flow information related to leases	3 Months Ended
	Aug. 31, 2020 USD ($)
Supplemental cash flow information related to leases [Abstract]
Operating cash flows from operating leases	$ 78,561
Right-of-use assets obtained in exchange for new operating lease liabilities
Weighted average remaining lease term (in years)	6 years 7 days
Weighted average discount rate	6.50%

XML 38 R27.htm IDEA: XBRL DOCUMENT

LEASES (Details) - The maturity of lease liabilities	Aug. 31, 2020 USD ($)
The maturity of lease liabilities [Abstract]
2021	$ 161,927
2022	236,391
2023	262,810
2024	291,328
2025	322,098
Thereafter	457,053
Total	$ 1,731,607

XML 39 R28.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	May 25, 2016	Jun. 25, 2020
University Of Texas Health Science Center [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Clinical Trial Agreement Maximum Budgeted Costs		$ 139,850
Telcon Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Accrued Fees and Other Revenue Receivable	$ 1,250,000
Stock Issued During Period, Shares, Other (in Shares)	83,333
Proceeds from Fees Received	$ 250,000
Royalty Percentage	15.00%

XML 40 R29.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details)	Oct. 05, 2020 USD ($)
Ukrainian Distributor [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Contract with Customer, Asset, Sale	$ 480,000

EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 42 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 71 262 1 false 38 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.biomerica.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Sheet http://www.biomerica.com/role/ConsolidatedIncomeStatement CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Statements 2 false false R3.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.biomerica.com/role/ConsolidatedBalanceSheet CONDENSED CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 4 false false R5.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited) Sheet http://www.biomerica.com/role/ShareholdersEquityType2or3 CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.biomerica.com/role/ConsolidatedCashFlow CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 006 - Disclosure - BASIS OF PRESENTATION Sheet http://www.biomerica.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 7 false false R8.htm 007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 008 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://www.biomerica.com/role/SHAREHOLDERSEQUITY SHAREHOLDERS' EQUITY Notes 9 false false R10.htm 009 - Disclosure - GEOGRAPHIC INFORMATION Sheet http://www.biomerica.com/role/GEOGRAPHICINFORMATION GEOGRAPHIC INFORMATION Notes 10 false false R11.htm 010 - Disclosure - LEASES Sheet http://www.biomerica.com/role/LEASES LEASES Notes 11 false false R12.htm 011 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 012 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.biomerica.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 13 false false R14.htm 013 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.biomerica.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies 14 false false R15.htm 014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES 15 false false R16.htm 015 - Disclosure - GEOGRAPHIC INFORMATION (Tables) Sheet http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables GEOGRAPHIC INFORMATION (Tables) Tables http://www.biomerica.com/role/GEOGRAPHICINFORMATION 16 false false R17.htm 016 - Disclosure - LEASES (Tables) Sheet http://www.biomerica.com/role/LEASESTables LEASES (Tables) Tables http://www.biomerica.com/role/LEASES 17 false false R18.htm 017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables 18 false false R19.htm 018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories Sheet http://www.biomerica.com/role/InventoriesTable SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories Details http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables 19 false false R20.htm 019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity Sheet http://www.biomerica.com/role/OptionsActivityTable SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity Details http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables 20 false false R21.htm 020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers Sheet http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers Details http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables 21 false false R22.htm 021 - Disclosure - SHAREHOLDERS' EQUITY (Details) Sheet http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails SHAREHOLDERS' EQUITY (Details) Details http://www.biomerica.com/role/SHAREHOLDERSEQUITY 22 false false R23.htm 022 - Disclosure - GEOGRAPHIC INFORMATION (Details) Sheet http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails GEOGRAPHIC INFORMATION (Details) Details http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables 23 false false R24.htm 023 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales Sheet http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales Details http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables 24 false false R25.htm 024 - Disclosure - LEASES (Details) Sheet http://www.biomerica.com/role/LEASESDetails LEASES (Details) Details http://www.biomerica.com/role/LEASESTables 25 false false R26.htm 025 - Disclosure - LEASES (Details) - Supplemental cash flow information related to leases Sheet http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable LEASES (Details) - Supplemental cash flow information related to leases Details http://www.biomerica.com/role/LEASESTables 26 false false R27.htm 026 - Disclosure - LEASES (Details) - The maturity of lease liabilities Sheet http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable LEASES (Details) - The maturity of lease liabilities Details http://www.biomerica.com/role/LEASESTables 27 false false R28.htm 027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES 28 false false R29.htm 028 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.biomerica.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.biomerica.com/role/SUBSEQUENTEVENTS 29 false false All Reports Book All Reports bmra-20200831.xml bmra-20200831.xsd bmra-20200831_cal.xml bmra-20200831_def.xml bmra-20200831_lab.xml bmra-20200831_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 46 0001513162-20-000216-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001513162-20-000216-xbrl.zip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�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end